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The Epstein-Barr virus (EBV) is a lymphotropic -herpes virus infecting over 90% of the
human adult population. A striking feature that the virus shares with other -herpes
viruses is its oncogenic potential. This transforming property can be observed as B cell
transformation in vitro and lymphomas as well as epithelial cancers in vivo, but most
immunocompetent individuals control EBV infection successfully without the occurrence
of disease.

Cells of the innate immune system act in synergy to provide a first line of defense
against pathogens. Here we describe that dendritic cells (DCs), matured with viral
products or mimics thereof, activated natural killer (NK) cells more efficiently than other
mature DC preparations. CD56brightCD16- NK cells, which are enriched in human
secondary lymphoid tissues, responded primarily to this DC activation. In fact, 100-fold
less tonsilar than peripheral blood NK cells were required to achieve the same protection
against EBV-mediated B cell transformation in vitro, indicating that innate immune
control of EBV by NK cells is most efficient at this primary site of EBV infection.

The lack of an animal model of EBV infection prevents assignment of a protective value
to immune subsets in vivo. We generated a small animal model that can be infected with

EBV by reconstituting NOD-scid c-/- mice with CD34+ hematopoietic stem cells. We
demonstrated that primary T cell responses in these humanized mice control infection
with EBV. These T cell responses were HLA restricted and partially specific for EBV
derived peptides. In HLA-A2 transgenic animals T cell responses against lytic EBV
antigens dominated over recognition of latent EBV antigens during early phases of
infection similarly to human EBV carriers. This mouse model recapitulates features of
symptomatic primary EBV infection, and generates T cell mediated immune control that
resists oncogenic transformation. We were also able to demonstrate that humanized
mice develop functional human NK cells, this will allow us now to study the contributions
of NK cells to innate immune control of EBV in vivo in the future.
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Introduction

1.1
1.1.1

The Epstein-Barr virus
History of the Epstein-Barr virus

The Epstein-Barr virus (EBV) was discovered in 1964 by Anthony Epstein, Yvonne Barr,
and Bert Achong when they analyzed cell lines from Burkitts lymphoma patients
(Epstein et al., 1964). By studying pictures taken by electron microscopy they found that
these cells were infected with a virus, which did not react with antisera that had been
established against the so far known herpesviruses. From then on, EBV has served as a
fascinating and useful model for virologists, immunologists, and clinical researchers
(Young and Rickinson, 2004). First, virologists have been particularly interested in EBV
as it was the first human virus that had been discovered to be associated with tumors.
Later, it was found that EBV encoded proteins contribute to the oncogenesis of tissues of
very different developmental origins such as lymphocytes and epithelial cells.
Immunologists, on the other side, studied the cellular immune response to a genetically
stable, persistent human virus. During the lytic and latent infection of EBV different sets
of proteins are expressed. It has been a center of attention to study the induction and
regulation of qualitatively different cellular immune responses to these different sets of
antigens. These efforts revealed interesting insights into mechanisms regarding
immunodominance hierarchies and the biological effectiveness of different immune
responses. EBV has also received significant attention by clinical researchers, because
soon after its discovery, it was shown that EBV is the causative agent of infectious
mononucleosis and that a high frequency of Burkitts and Hodgkins lymphoma cell lines
are also EBV positive. More recently, EBV has been implicated as a potential
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environmental trigger for complex autoimmune diseases such as multiple sclerosis and
systemic lupus erythematosus. In conclusion, these results demonstrate that EBV
provides a valuable system to advance the understanding of the development of
protective immune responses against persistent viruses in humans in general.
1.1.2

Basic biology of herpes virus infections

EBV belongs to the family of herpes viruses and is one of eight known members
infecting humans (Thorley-Lawson and Allday, 2008). Upon transmission to a naive host,
the herpes viruses first amplify the viral load through replicative (lytic) infection in a
permissive cell type - in the case of EBV the infection occurs in a B cell (Young and
Rickinson, 2004). Then the virus persists for the life of the host as an asymptomatic
latent infection in the same or a different second cell type. Occasionally, the virus
reactivates into the lytic cycle and produces infectious virions that are transmissible to a
new host. For all herpes viruses the lytic cycle is characterized by the sequential
expression of immediate early genes (IE), followed by early genes (E) and late genes
(L). In contrast, the establishment of the latent cycle is different between the three subfamilies of herpes viruses. While - and -herpes viruses immediately shut down the
viral protein expression after entering their target cell, -herpes viruses express a set of
proteins encoded by latent cycle genes that appear to be crucial for the establishment of
the latent state. The transient expression of all or part of these genes is associated with
a phase of cell proliferation that serves to amplify the latently infected cell pool.
Thereafter, the expression is suppressed to give a stable reservoir of virus-infected cells
that do not express viral proteins.
The gamma viruses themselves are divided into two genera, -1 and -2, with different
sets of latent cycle genes and apparently different molecular strategies for the induction
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of latent cell proliferation. The Karposis sarcoma herpes virus (KSHV) and its distant
relative murine -herpesvirus 68 (MHV-68) are classical -2 viruses. They establish
latency in B cells, but have no independent capacity to drive B cell growth. From the
evidence of MHV-68, amplification of the latent antigen-expressing B cell pool occurs
within germinal centers and requires T cell help. In contrast, the more recently evolved
genera of gamma-1 viruses or lymphocrytoviruses, including EBV, are only found in
primates and have acquired direct B cell growth-transforming ability.
1.1.3

Biology of the EBV infection

EBV is an almost ubiquitous virus infecting around 90 – 95 % of the human population.
In many countries with poorer hygienic conditions, the EBV infection takes place already
during infancy and is asymptomatic (Young and Rickinson, 2004). In countries with
higher hygienic standards the primary infection can be delayed until the second decade
or later. In up to 25 – 50 % of cases of delayed primary infection, the infection is not
asymptomatic but can present itself as infectious mononucleosis (IM)(Crawford et al.,
2006). IM is an acute but self-limiting illness characterized clinically by fever, sore throat,
and swollen lymph nodes. Based on the assumption that IM is a magnified version of
asymptomatic primary infection, studies with IM patients and in vitro models have been
used to characterize the initial events during primary infection (Hislop et al., 2007).
According to this model, EBV replicates in a permissive cell type in the oropharynx after
oral transmission (Figure 1) (Young and Rickinson, 2004). This lytic infection leads to
high rates of virus shedding into the throat, which is only slowly brought under control by
the immune system. At the same time, the virus infects mucosal B cells and initiates a
latent growth-transforming infection, leading to the expansion of lymphoblastoid cell line
(LCL)-like cells in the extrafollicular areas of tonsillar lymphoid tissues and the
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appearance of large numbers of infected cells in the blood (Thorley-Lawson, 2001).
Although many of these proliferating cells that express high amounts of viral antigens are
removed by the immune response, some survive by down-regulating latent antigen
expression and entering a resting state as members of the long-lived memory B cell
pool. Subsequently, these cells persist as a recirculating population, predominantly
found in blood and pharyngeal lymphoid tissues and very likely are subject to the same
physiologic constraints for cell survival and turnover as the memory B cell pool as a
whole. Thus, physiological events, such as antigen stimulation and receipt of a plasma
cell differentiation signal, might drive occasional reactivations into lytic cycle. During viral
latency a set of eight proteins including Epstein-Barr nuclear antigen (EBNA) 1, EBNA2,
EBNA3A, EBNA3B, EBNA3C, EBNA leader protein (EBNA-LP) and latent membrane
proteins (LMP) 1, LMP2A/B is expressed (Thorley-Lawson, 2001). Different patterns of
latent protein expression have been found in infected individuals. Latency I is
characterized by the sole expression of EBNA1 and is in vivo found in dividing EBV
positive memory cells as well as in most Burkitts lymphoma cells. In latency II LMP1,
LMP2 and EBNA1 are expressed and this profile is commonly found in Hodgkins
lymphoma, NK/T cell lymphomas, and uterine leiomyosarcoma. Notably, in gastric and
nasopharyngeal carcinomas both latency I and latency II can be found. Finally, in latency
III the full set of latent proteins including EBNA1, EBNA2, EBNA3A/B/C, EBNA-LP and
LMP1/2 are expressed (Thorley-Lawson, 2001). Latency III is only found in vitro in LCLs
and in vivo in lymphomas of immunosuppressed patients. Interestingly, during latency
EBV expresses also a number of non-coding RNAs including the commonly expressed
Epstein-Barr encoded RNAs (EBERs) and in addition at least twenty microRNAs.
However, so far the expression patterns and functions of these microRNAs have not
been fully determined.
4

Figure 1: Life cycle of EBV. a) Primary infection. The incoming virus establishes a primary focus of lytic
replication in the oropharynx after which the virus spreads throughout the lymphoid tissues as a latent
(latency III) infection of B cells. Many of these proliferating cells are removed by the emerging immune
response, but some escape by down-regulating antigen expression and establishing a stable reservoir of
resting viral-genome-positive memory B cells, in which viral antigen expression is mostly suppressed
(latency 0/I) b) Persistent infection. The reservoir of EBV-infected memory B cells becomes subject to the
physiological controls governing memory-B-cell migration and differentiation as a whole. Occasionally, these
EBV-infected cells might be recruited into germinal-centre reactions, entailing the activation of different
latency programmes, after which they might either re-enter the reservoir as memory cells or commit to
plasma-cell differentiation — possibly moving to mucosal sites in the oropharynx and, in the process,
activating the viral lytic cycle. Virions produced at these sites might initiate foci of lytic replication allowing
low-level shedding of infectious virus in the oropharynx, and might also initiate new latency III infections of
naive and/or memory B cells; these new infections might possibly replenish the B-cell reservoir. (Adapted
from Young and Rickinson, 2004)

1.2

Control of viral infections by the innate immune response

The immune system preserves the integrity of its host by recognizing and resisting
invaders. Therefore, evolution has provided each species with the capacity to resist the
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pathogenic challenges in its ecological niche. The innate and the adaptive immune
system are the two arms of the immune system that provide indispensable protection of
the host against pathogenic invaders. The innate immune system is the evolutionary
older part of the immune system and consists of a number of different cell types and
mechanisms that provide important non-specific restriction of infections (Medzhitov and
Janeway, 1997). But unlike the adaptive immune system it is thought to provide no longlasting immunity against secondary infections of the same pathogen. The most important
functions of the innate immune system are the identification or sensing of an infection of
the host, the recruitment of other immune cells to the site of insult through the production
of chemokines and cytokines, the removal of foreign substances by phagocytosis, the
early protection against microbial pathogens and finally the activation of adaptive
immune cells by antigen-presentation (Medzhitov and Janeway, 1998).

1.2.1

Sensing the viral infection by immune and non-immune cells

The recognition of foreign invaders is crucial to mount any immune response by the host
and the question how the immune system achieves this difficult task has been debated
extensively. Competing theories have been proposed by Charles Janeway and Polly
Matzinger around 15 years ago suggesting that the immune system recognizes either
so-called pathogen-associated molecular patterns (PAMPs) or endogenous danger
signals, respectively (Janeway, 1992; Matzinger, 1994). However, both of these theories
are now widely accepted and the identity of a number of receptor systems to recognize
danger signals or PAMPs has been described. According to Matzingers theory, danger
signals could be either active signs or passive signs of distress that are released actively
or passively, respectively, when cells are stressed, infected with a pathogen or when
tissue is damaged. One of these danger signals is the protein high-mobility group B1
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(HMGB1), a nuclear protein well characterized in terms of its ability to modify DNA
access for transcriptional proteins (Erlandsson Harris and Andersson, 2004). It also
interacts with high-affinity receptors for advanced glycation end products (RAGE) and
Toll-like receptor (TLR) 2 on dendritic cells (DCs). Other signals are crystalline uric acid
or ATP that are released from dying cells and which activate the NALP3 inflammasome,
an innate immune complex that controls inflammatory caspases and IL-1 activation
(Petrilli et al., 2007). But, the immune system is also able to directly sense the presence
of pathogens via the recognition of molecules or molecular structures that are not
commonly found in the host such as unmethylated DNA, double stranded RNA (dsRNA)
or lipopolysaccharides (LPS). In particular, phagocytes are equipped with several cellsurface receptors that recognize pathogen surfaces directly. In addition to triggering
phagocytosis, binding of pathogens by dendritic cells and macrophages can also trigger
induced responses of the innate immunity, and responses that eventually lead to the
induction of the adaptive immunity (Iwasaki and Medzhitov, 2004). The best-defined
activation pathway of this type is triggered through a family of evolutionarily conserved
transmembrane receptors, called TLRs. They contain an ectodomain of leucine-rich
repeats (LRR), a transmembrane domain and a cytoplasmatic domain known as Toll/IL-1
receptor (TIR) domain. These receptors were first described in adult flies where the Toll
signaling pathway induces the production of several antimicrobial peptides that
contribute to the flys defense against infection (Lemaitre et al., 1996). In contrast to the
fly where Toll serves as a regulator, the 10 TLRs in humans facilitate the direct
recognition of microorganisms via the variable LRR region that interacts with such
diverse structures such as LPS (recognized by TLR4), bacterial flagellin (TLR5), or
dsRNA (TLR3). TLR activation by their cognate agonists leads to the recruitment of
cellular adaptor molecules that contain TIR domains and the formation of multi7

component signal transduction complexes in the cytoplasm (Takeda et al., 2003).
Signaling downstream of TLRs initiates the transcription of genes encoding cytokines,
chemokines, and co-stimulatory molecules. Besides TLRs there are at least two other
families of pathogen recognition receptors (PRRs), the family of RIG-I-like receptors
(RLRs) recognizing viral infection and dsRNA and the family of Nod-like receptors
(NLRs) recognizing bacterial infection (Meylan et al., 2006). It is thought that the
interplay between these families ensures the efficient coordination of innate immune
responses, through either synergistic or cooperative signaling. With respect to herpes
virus infections, it was demonstrated that indeed in addition to TLR2, TLR3, and TLR9,
RIG-I also synergizes with TLR receptors in the induction of interferon production after
sensing of murine herpes simplex virus (Lund et al., 2003; Rasmussen et al., 2009; Sato
et al., 2006; Tabeta et al., 2004). In the case of EBV, it was shown that EBV is
recognized via TLR2 in monocytes resulting in the production of inflammatory cytokines
such as MCP-1 (Gaudreault et al., 2007). In addition, EBV induces plasmacytoid DC to
produce IFN- in a TLR9-dependent manner (Lim et al., 2006). Therefore, PRRs
contribute to the recognition of EBV by the immune system enabling the activation and
priming of immune responses that allows control of acute and persistent infection by this
human tumorvirus.

1.2.2

Basic biology of dendritic cells

Paul Langerhans first described morphologically a subset of dendritic cells in the skin in
the late nineteenth century, which were later called Langerhans cells and were initially
thought to be part of the nervous system. However, it was Ralph Steinman and Zanvil
Cohen who identified dendritic cells (DC) in 1973 as a functionally distinct subset of
immune cells (Steinman and Cohn, 1973). DCs serve as sentinels for the immune
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system, patrolling the periphery surveying their environment for signs of danger or
infection with pathogens (Figure 2). Upon activation which is called maturation, they
change their phenotype and become potent activators of the innate and adaptive
immune system (Banchereau and Steinman, 1998). DCs arise in the steady state from a
common progenitor within the bone marrow, which is Lin-Flt3+M-CSFR+ in mice (Naik et
al., 2007; Onai et al., 2007). DCs can be divided morphologically and functionally into
two types: conventional DCs (cDCs), and plasmacytoid DCs (pDCs). Conventional DCs
consist of several subsets that are distinguished according to surface markers such as
Langerin, CD11c in addition to CD11b and CD8a in mice and BDCA1, BDCA3, and
CD16 in humans, respectively (Shortman and Liu, 2002). Importantly, these subsets can
also be distinguished by functional aspects such as antigen processing and presentation
(Dudziak et al., 2007; Soares et al., 2007). The precursor of cDCs emerges from the
bone marrow to migrate in the blood to peripheral tissues to develop into different
subsets of immature DCs. In contrast, plasmacytoid DCs are thought to be a relative
homogenous population that develops completely in the bone marrow and can later be
characterized by their ability to secrete large amounts of type I interferons (IFNs) in
response to viruses and/or TLR7/9 ligands (Gilliet et al., 2008). Under inflammatory
conditions, monocytes can also differentiate into so-called monocyte-derived DCs
(moDCs)(Auffray et al., 2009). Notably, because of the low frequency of human DCs in
the peripheral blood (~ 0.5 %) in vitro derived human moDCs have served as valuable
model for human DCs.
In the steady state and during an immune response, DCs are specialized to capture and
process antigens in vivo, converting proteins to peptides that are presented on major
histocompatibility complex (MHC) molecules and recognized by T cells (Banchereau and
Steinman, 1998).
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Figure 2: DCs as immune sensors of life, death and danger. Dendritic cells express many different
receptors, including TLRs, which enable them to sense life (bacteria, viruses, parasites, fungi etc) and death
(uric acid crystals and gp96 and hsp70 from necrotic cells, apoptotic bodies, etc). Many signals of life and
death can harm the integrity of the local tissues and of the host itself — thus these constitute clear danger
signals for the host. DCs rapidly become activated in response to such signals, and result in immune
activation and inflammation. In contrast, quietly dying apoptotic cells or other undefined signals that
represent no harm to the integrity of the host may not activate dendritic cells or immune responses and may
lead to immune quiescence or tolerance. (From Pulendran 2008)

While DCs or subsets of DCs slowly, but continuously traffic into secondary lymphoid
organs to present antigens, the migration of DCs to lymph nodes (LNs) is pivotal for the
establishment of an immune response. To enter LNs from the peripheral tissues DCs
pass through the afferent lymphatic pathway. In the LNs, T cells scan the MHC/peptide
complexes on DCs and after recognition of cognate antigens on DCs, T cells may
undergo extensive expansion with devision rates of as high as 2–3 cell cycles a day with
the appropriate costimulation provided (Steinman and Banchereau, 2007). However,
clones of lymphocytes are also subject to silencing or tolerance by tolerogenic DCs,
which either eliminate or suppress T cells. cDCs are recruited to inflamed tissues in
response to inflammatory chemokines and then remobilized to regional LNs. In contrast,
pDCs directly transmigrate to regional LNs via high endothelial venules. In addition to
their important function as uniquely powerful antigen-presenting cells, DCs secrete a
number of immunostimulatory cytokines such as IL-12 or IFN- after stimulation that not
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only influence the strength and quality of the adaptive immune responses, but also
regulate other innate immune cells such as natural killer cells (NK cells) (Steinman and
Banchereau, 2007). The ability of DCs to regulate both arms of the immune system
makes them to important master regulators during both, steady state and inflammation.

1.2.3

Dendritic cells during viral infections

During a viral infection, DCs can be matured either through PAMPs, danger signals, or
through cytokines secreted by other immune cells. In addition, viruses may also infect
DCs by binding to surface molecules, or after being engulfed but not destroyed which
can lead to the activation of the cell. In order to recognize viruses, DCs express TLRs
recognizing either nucleic acids or structural components of viruses (Iwasaki and
Medzhitov, 2004). In particular, pDCs express TLR7 and TLR9 enabling them to
recognize ssRNA and DNA viruses, respectively, and produce rapidly large amounts of
type I interferons (Gilliet et al., 2008). cDC express a different set of TLRs that are
important during viral infections, namely TLR2, TLR3 and TLR8, that enable cDCs to
recognize viral glycoproteins, dsRNA, or ssRNA, respectively and induce the production
of type I interferons and proinflammatory cytokines such as IL-12 (Iwasaki and
Medzhitov, 2004). These cytokines secreted by DCs fulfill several important functions,
they i) activate immune cells, ii) induce an antiviral state in cells and iii) determine the
type of adaptive immunity induced. In addition, after the uptake of viral antigens by
phagocytosis or the direct synthesis of viral antigens in DCs, virally-derived peptides are
expressed on the surface on both MHC class I and II molecules. This generates DCs
that are able to activate naive CD8 T cells in order to generate cytotoxic CD8 effector T
cells and also to activate CD4 T cells. Then, these CD4 T cells are important for helping
CD8 T cells (Th1) and for the production of antibodies by B cells (Th2), but moreover
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can also have direct effector functions. Whether DCs stimulate Th1 or Th2 responses
depend on the maturation stimulus, particularly on its molecular and physical nature
(Iwasaki and Medzhitov, 2004).
Since DCs play such a crucial role in the induction of antiviral responses, many viruses
have developed strategies to evade recognition and interfere with the functions of DCs.
Numerous stages during the initiation of immunity by DCs have been targeted for
inhibition by viruses and bacteria. These include antigen detection, DC maturation, DC
migration, antigen presentation to lymphocytes by DCs, and effector cytokine release
leading to a defect in immune function of DCs (Trifilo et al., 2006). For example, Toll-like
receptors, acting as DC detector systems for viral and bacterial byproducts, have
recently been shown to be targets for inhibition by viral infection (Kopp and Medzhitov,
2003). Specifically, vaccinia virus was found to block signaling of Toll-like receptors,
resulting in the complete inhibition of DC maturation and immunosuppression of the host
(Bowie et al., 2000). Another effective immune evasion strategy is the impairment of
antigen presentation by DCs, which aborts T cell stimulation and either prevents
activation of or nonproductively activates antigen-specific T cells. The ability to disrupt
antigen presentation has evolved in many virus families, including adenoviruses, HIV,
and herpesviruses (Rinaldo and Piazza, 2004).
A classical example for the generation of immune responses by DCs during viral
infection is the beta-herpes virus murine cytomegalovirus (MCMV). During the early
phases of infection with the MCMV, murine pDC and cDC collaborate to induce effective
innate and adaptive immune control of the virus (Delale et al., 2005; Krug et al., 2004).
After sensing the virus using multiple TLRs, pDCs and cDC are induced to produce type
I interferons, TNF-, and IL-12p70 that activate NK cells and polarize a Th1 adaptive
immune response (Andoniou et al., 2005; Delale et al., 2005). In the case of MHV-68,
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DCs were found to produce IL-12, IFN- and IL-6 in vitro in a TLR9-dependent manner.
Finally, the recognition of EBV by pDCs was shown to activate NK cells and T cells to
produce IFN- (Lim et al., 2006). Furthermore, moDCs were found to efficiently prime T
cell responses in EBV sero-negative individuals in vitro (Bickham et al., 2003). The
combination of these abilities of DCs to sense viral infections and then to activate innate
and adaptive immunity accordingly makes DCs crucial players in anti-viral immune
responses and their role during EBV infection needs to be further evaluated.

1.2.4

NK cells and NK cell subsets

NK cells were originally described as a homogenous population of innate lymphocytes
characterized by their ability to spontaneously kill target cells (Herberman et al., 1975b;
Kiessling et al., 1975; Trinchieri, 1989). However, already in the 1980s, it was proposed
that human NK cells in peripheral blood can be divided into at least two subsets based
on the expression of CD56 and CD16 (Table 1) (Lanier et al., 1986).The major subset of
CD56dimCD16+ NK cells constitutes around 90 % of total blood NK cells, kills target cells
upon proper recognition and secretes only low levels of IFN- (Cooper et al., 2001). In
contrast, CD56brightCD16- NK cells (<10% of total blood NK cells) produce large amounts
of cytokines including IFN-, TNF and GM-CSF upon stimulation by pro-inflammatory
cytokines, but acquire cytotoxicity only after prolonged activation. Further differences
between the subsets have also been found with respect to expression of inhibitory and
activating receptors. While CD56brightCD16- NK cells express high levels of the inhibitory
CD94/NKG2A complex recognizing HLA-E, they do not express MHC class I allelespecific killer-inhibitory receptors (KIRs) that are in contrast expressed by CD56dimCD16+
NK cells. Regarding the expression of activating receptors, both NK cell subsets in
human peripheral blood express the activating receptors NKG2D and NKp30 as well as
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NKp46, whose ligands are induced in pathogen-infected or stressed cells. Yet a major
discrepancy exists between the two subsets in the expression of the antibody dependent
cellular cytotoxicity (ADCC) mediating CD16 (FcRIII) receptor which is only present on
the CD56dim subset (Jacobs et al., 2001; Moretta et al., 2001). Finally, NK cell subsets
also differ in the expression of chemokine receptors. Cytotoxic CD56dimCD16+ NK cells
express CXCR1 and CX3CR1 and respond to IL-8 and fractalkine, the respective ligands
for these receptors (Campbell et al., 2001). Interestingly, only CD56bright NK cells express
secondary lymphoid organ (SLO) homing markers such as CCR7, CD62L, and CXCR3,
resulting in an enrichment of this subset in SLO and sites of inflammation, respectively
(Campbell et al., 2001; Fehniger et al., 2002; Ferlazzo et al., 2004b). The question of
whether or not the development of the human subsets interconnected has been under
investigation for some time. Recently, a number of studies suggested that
CD56brightCD16- NK cells are able to differentiate into CD56dimCD16+ NK cells upon
prolonged activation (Chan et al., 2007; Romagnani et al., 2007).
Murine NK cells share a lot of the properties of human NK cells, but since they do not
express the homologue of CD56, it has proven to be difficult to identify functionally
different NK cell subsets in mice. More recently however, several studies showed the
presence of functionally different NK cell subsets in mice (Table 1) (Blasius et al., 2007;
Hayakawa and Smyth, 2006; Vosshenrich et al., 2006). The first study suggested
differentiating mature NK cells according to their expression of CD27 into Mac1highCD27+
and Mac1highCD27- subsets (Hayakawa and Smyth, 2006). Although these two subsets
differ in the expression of inhibitory and activating receptors as well as chemokine
receptors, there are striking differences between human and mouse subsets. Most
importantly, Mac1highCD27+ NK cells are superior to Mac1highCD27- cells in both the
production of cytokines as well as cytotoxicity, whereas in human NK cell subsets
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CD56brightCD16- NK cells are superior in IFN- production, but are not cytotoxic. In
another study, a new developmental pathway for a distinct NK cell subset was described
in the thymus (Vosshenrich et al., 2006). These cells are characterized by expression of
the IL-7 receptor, CD127, and the transcription factor GATA-3. Interestingly, this subset
resembles human CD56brightCD16- NK cells in expression of CD127, lower expression of
inhibitory molecules and cytotoxic molecules, yet higher cytokine production after IL-12
stimulation. Furthermore, this subset seems to be enriched in lymph nodes compared to
other NK cells although to a lesser degree compared to humans (15-30 % vs. 75 %,
respectively) (Ferlazzo et al., 2004b; Vosshenrich et al., 2006). It remains unclear so far
which functions this NK cell subset has in vivo, and how closely its development reflects
CD56brightCD16- NK cell generation in humans, given the previously discussed
experimental evidence for a linear instead of a separate development of the two
functionally diverse NK cell subsets in humans. In the third study, NK1.1+B220+CD11c+
NK cells were found to be enriched in secondary lymphoid tissues and to secrete higher
levels of IFN- compared to other mouse NK cells (Blasius et al., 2007). However, NK
cells of this subset also killed classical NK cell targets efficiently (Caminschi et al., 2007),
and CD11c, B220 and MHC class II were upregulated on NK1.1 cells upon activation
(Vosshenrich et al., 2007). Thus, NK1.1+B220+CD11c+ cells might represent in vivo
activated NK cells rather than the mouse equivalent of human CD56brightCD16- NK cells.
Nevertheless, the discovery of functionally different NK cell subsets in humans and mice
has extended the field of NK cell research tremendously and yielded insight into
important non-cytotoxic functions of NK cells.
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Table 1: Differences between human and murine NK cells
Affected Aspect

Mouse

Human

Subsets:
NK cell subsets enriched
in SLO
NK cell subsets enriched in
blood
Frequency:
LN
Spleen
Blood

Mac1highCD27+ (high/high)*
CD127+GATA-3+ (low/high)
CD11c+B220+ (high/high)
Mac1highCD27– (low/low)
CD127–GATA-3– (high/low)
CD11c–B220– (low/low)

0.1 – 0.3%
2-3%
2-3%

Receptor/ligand interactions:
Natural cytotoxicity receptors
NKp46
Ligands for the activating NK cell
Rae1, H60, MULT-1
receptor NKG2D
Inhibitory receptors for MHC
Ly49
class Ia molecules
*: indicates cytotoxicity/IFN- secretion

1.2.5

CD56brightCD16– (low/high)

CD56dimCD16+ (high/low)

1 – 5%
7 – 50 %
7 – 25 %

NKp30, p44, p46
MICA/B, ULBP1–4, RAET1G
Killer cell Ig-like receptors

Tissue distribution and trafficking of NK cells

In line with their role in innate immunity and immune surveillance, NK cells are widely
distributed in mammals, yet, intriguingly, the distribution of NK cell subsets differs
between distinct anatomical sites, suggesting a specialization of NK cell subsets
(Ferlazzo and Munz, 2004; Ferlazzo et al., 2004b; Gregoire et al., 2007; Trinchieri,
1989). In humans, the CD56brightCD16- subset is markedly enriched in SLO, making up to
75 % of NK cells in lymph nodes and 50 % in the spleen (Ferlazzo et al., 2004b). As
lymph nodes are suggested to harbor 40% of all human lymphocytes, whereas probably
only 2% of all lymphocyte circulate through peripheral blood at any given moment,
CD56brightCD16- NK cells in SLO constitute a remarkable pool of innate effector cells in
humans. In mice, the distribution of NK cells subsets is also different as Mac1+CD27high,
CD127+ and B220+CD11c+ NK cells are all enriched in lymph nodes, whereas they
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represent minor subsets in spleen and peripheral blood (Hayakawa and Smyth, 2006;
Vosshenrich et al., 2006). In general, while mouse NK cells are mainly excluded from B
and T cell areas in both spleen and lymph nodes in the steady state, human NK cells are
present at significant levels of 1-5% of all mononuclear lymph node cells in perifollicular
T cell zones in these secondary lymphoid organs (Table 1) (Fehniger et al., 2002;
Ferlazzo et al., 2004a; Gregoire et al., 2007). Their localization in perifollicular regions in
lymphoid organs potentially positions them to interact with incoming DCs that arrive
through the afferent lymph. Notably, in human lymph nodes NK cells can be found in
close proximity to resident DCs, furthermore intra-vital microscopy of mice revealed that
NK cells were crawling and communicating with their environment in lymph nodes,
forming contacts with DCs (Bajenoff et al., 2006; Ferlazzo et al., 2004a; Garrod et al.,
2007). But, NK cells can not only be found in lymphoid tissues, also lung, liver and skin
have been shown to harbor significant numbers of NK cells in both mice and humans.
Finally, NK cell distribution is not static as NK cells can recirculate between organs in a
subset-specific manner (Gregoire et al., 2007). In addition to their distribution and
recirculation in the steady state, NK cells are recruited to sites of inflammation
(Trinchieri, 1989). Detailed analysis of mouse NK cells showed that they can be recruited
to lymph nodes, lung, liver, and central nervous system during infections. These NK cells
apparently mainly originate from the spleen and the bone marrow as NK cell numbers
decrease in these organs as they increase in other organs (Wald et al., 2006). Due to
their expression of chemokine receptors such as CCR2, CCR5, CXCR3, and CX3CR1,
NK cells are able to respond to a large array of inflammatory cytokines (Colucci et al.,
2003; Gregoire et al., 2007). As discussed above, NK cell subsets in both man and
mouse differ in the expression of certain chemokine receptors. Notably, in humans
mainly CD56bright CD16- and only few CD56dimCD16+ NK cells were found in a number of
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inflammatory sites suggesting that the CD56brightCD16- NK cell subset is specifically
recruited to sites of infection, inflammation and tumorigenesis (Carrega et al., 2008;
Dalbeth et al., 2004; Ottaviani et al., 2006). Finally, inflammation also causes a
redistribution of mouse NK cells in spleen and lymph nodes into T cell zones into close
proximity of DCs (Bajenoff et al., 2006). The CXCR3-dependent recruitment to the lymph
node in the mouse might be very different from the situation in humans as human
CD56brightCD16- NK cells express the lymph node-homing molecule CCR7 and are found
in significant numbers also in non-inflamed lymph nodes (Fehniger et al., 2002; Ferlazzo
et al., 2004b; Martin-Fontecha et al., 2004). Additionally, separate NK cell development
to CD56bright CD16- NK cells in lymph nodes also contributes to the enrichment of this NK
cell subset at these sites (Freud et al., 2005). Furthermore, in the non-inflamed human
spleen, NK cells are found in close proximity to DCs in T cell zones, again demonstrating
species-specific differences (Ferlazzo et al., 2004a). Altogether the analysis of the
distribution and localization as well as the recruitment of NK cells and more recently of
NK cell subsets in mouse and man has provided important insight into NK cell biology,
highlighted differences between the species and led to the discovery of new functions of
NK cell subsets.

1.2.6

Activation of NK cells during innate immune responses

Initially, NK cells were recognized for their ability to mediate spontaneous cytotoxicity
against target cell lines, however, it was later discovered that additional signals were
needed for NK cells to become fully activated. Numerous studies in humans and mouse
models both in vivo and in vitro found that these signals can be provided by DCs
(Ferlazzo et al., 2003; Ferlazzo et al., 2002; Fernandez et al., 1999; Gerosa et al., 2002;
Piccioli et al., 2002; Yu et al., 2001). The activation of NK cells was demonstrated to be
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mediated directly by cell-cell contact and indirectly via the secretion of cytokines such as
type I interferons or monokines such as IL-12, IL-15, and IL-18 (Figure 3). Among the
soluble factors, IL-12 has been repeatedly observed to induce IFN- secretion and
proliferation and was thought to be the most pivotal signal enhancing factor for NK cell
effector functions in humans and in mice (Ferlazzo et al., 2004a; Orange and Biron,
1996a; Orange and Biron, 1996b; Yu et al., 2001). Yet, a recent study suggests that IL15 acts as an even earlier and more crucial regulator of NK cell differentiation and
function at least in mice (Lucas et al., 2007). After in vivo stimulation with TLR ligands or
bacterial and viral infection, it was shown that myeloid CD11chigh DCs need to prime NK
cells via presentation of IL-15 to produce IFN- and become cytotoxic against a MHC
class I low cell line expressing NKG2D ligands. Curiously in analogy to adaptive T cell
responses, NK cells needed to enter the draining lymph node to receive the priming
signal to subsequently perform effector functions in the periphery. In humans, we have
recently shown that IL-15 receptor alpha colocalizes at the synapse between DCs and
NK cells and contributes to NK cell survival (Brilot et al., 2007). Closer characterization
of this synapse revealed that both activating signals such as mediated by IL-15 and
inhibitory signals such as interactions of CD94/NKG2A and KIRs with MHC class I
molecules are transmitted in spatially separated domains within the center of this
synapse. The regulatory DC/NK cell synapse was formed very rapidly (1-5min), lasted
for long time periods (10min) and was distinct from activating NK cell synapses formed
with classical MHC class Ilow NK cell targets (Davis and Dustin, 2004; Vyas et al., 2002).
Strikingly, DCs are protected from NK cell killing, although intracellular Ca2+ levels rise in
NK cells upon interaction which have been correlated with killing of target cells (Brilot et
al., 2007; Vyas et al., 2002). Notably, at later timepoints (>20 min) DCs seem to polarize
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preformed vesicles of IL12 to the synapse providing further activation signals to
conjugated NK cells (Borg et al., 2004). These studies suggest that efficient NK cell
activation and maintenance requires synapse formation with DCs.
Based on previous studies the different NK cell activating cytokines were believed to
mediate different aspects of DC-induced NK cell stimulation and steer the innate immune
response to distinct NK cell effector functions. While type I interferons, mainly secreted
by plasmacytoid but also myeloid DCs are predominantly involved in the upregulation of
NK cell-mediated cytotoxicity, IL-12 and IL-18 were found to influence IFN- production
by NK cells (Andrews et al., 2003; Dalod et al., 2002; Nguyen et al., 2002; Orange and
Biron, 1996a; Orange and Biron, 1996b). Finally, in vitro studies suggest that another
pathway for the activation / coactivation of NK cells might be the direct recognition of
microbial products via TLRs or of infected cells via NKG2D/NCRs (Becker et al., 2003;
Girart et al., 2007; Moretta et al., 2000; Pende et al., 2002; Schmidt et al., 2004; Sivori et
al., 2004). These distinct pathways of NK cell activation might converge to regulate and
activate different arms of NK cell effector functions, and thereby tailor the NK cell
response to the needs of the particular immune response.
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Figure 3: DCs can affect NK cell functions by inducing the activation and/or proliferation of NK cells.
DC-mediated activation of NK cells, which results in increased NK-cell cytolytic activity and/or interferon(IFN-) production, can be induced by both resting and activated DCs, although the latter are more potent
activators. Both cell-contact-dependent interactions and soluble cytokine signals are involved. NKG2D (NK
group 2, member D) ligands that are expressed by DCs in response to appropriate stimuli have been
implicated. A role for adhesion molecules has also been indicated by the finding that LFA1 (lymphocyte
function-associated antigen 1)–ICAM1 (intercellular adhesion molecule 1) interactions are important for DCmediated activation of NK cells. The relevance of interactions mediated by CD70–CD27, CD48–2B4 and
CLRB (C-type-lectin-related B)–NKR-P1B (NK-cell receptor protein 1B) or NKR-P1D requires assessment.
Cytokine signals are essential for NK-cell activation, and several cytokines are involved (a). DC-derived
cytokines have also been implicated in DC-mediated proliferation of NK cells (b). Reciprocally, NK cells can
affect DC functions and lead to DC activation (c) or DC elimination (d). NK-cell-mediated activation of DCs
seems to depend mainly on cytokines, principally tumour-necrosis factor (TNF) and IFN- (c), whereas cellcontact-dependent interactions are required for DC elimination (d). IL, interleukin; NKp30, NK-cell protein 30;
TLR, Toll-like receptor; TRAIL, TNF-related apoptosis-inducing ligand. (Degli-Esposti et al., 2005)
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1.2.7

The role of NK cells in viral immunity

As previously discussed, NK cells are readily recruited and activated at sites of viral
infections. Traditionally, NK cells have been recognized for their protective role by
directly killing infected cells. Intriguingly, the cytolytic activity of fully matured NK cells is
controlled by the balance between inhibitory and activating signaling pathways (Moretta
et al., 2001). To prevent killing of normal cells, most NK cells express an array of
inhibitory receptors, many of which recognize major histocompatibility complex (MHC)
Class I molecules, expressed by almost all nucleated cells (Kumar and McNerney,
2005). This observation led to the missing-self hypothesis, whereby the postulated role
of NK cells is to destroy cells that express decreased levels of MHC Class I
molecules(Ljunggren and Karre, 1990). Indeed, MHC class I molecules are often downregulated in virally infected and cancer cells, supposedly a trait selected for avoiding
cytotoxic T-lymphocyte (CTL) recognition (Tortorella et al., 2000). The binding of MHC
class I complexes to KIRs or to the heterodimeric CD94/NKG2A receptor initiates
inhibitory pathways that can override activation signals (Natarajan et al., 2002). On the
other hand, reduced expression of MHC Class I is not the only requirement for NK cell
activation, and overexpression of activating ligands on target cells can also trigger NK
cell function. Moreover, absence of MHC class I only translates into NK cell recognition if
activating NK cell receptors are also engaged by activating structures on the MHC class
I low target cell. However, in addition to their cytolytic abilities, it has been established
that cytokines such as IFN- and TNF-, produced by NK cells, contribute to the control
of multiple murine and human infections (Biron et al., 1999). The effects of IFN- in
innate immunity are manifold, ranging from strengthening intrinsic immunity via the
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induction of antiviral factors or degradative pathways in exposed cells, to the activation
of other innate lymphocytes such as macrophages (Boehm et al., 1997).
The most prominent example of innate immune control of a herpesvirus by NK cells is
the murine cytomegalovirus (MCMV), a -herpesvirus. Innate resistance to this virus via
cytotoxicity is mediated by NK cells that carry the Ly49H activating NK cell receptor
(Daniels et al., 2001; Lee et al., 2001). Mouse strains susceptible to acute fatal MCMV
infection lack Ly49H, and Ly49H transgene expression confers resistance to MCMV in
these mice (Lee et al., 2003). Not unlike NKp46, this receptor selectively recognizes a
viral surface protein on infected cells called m157 (Arase et al., 2002). In MCMV
infection it was also further shown that DC-activated NK cells produce IFN- that directly
contributes to control viral infection (Andrews et al., 2003; Orange et al., 1995).
Moreover, it was demonstrated that NK cells can protect the host via secretion of IFN-,
but not as efficiently as in combination with cytotoxicity (Loh et al., 2005). IFN- directly
inhibits replication of MCMV, protecting against virus-induced pathogenesis and lethality
(Presti et al., 1998; Scalzo et al., 2007). In addition, IFN- is also critical for efficient
clearance of persistent viral replication and suppresses MCMV reactivation from latency
(Presti et al., 1998). Notably, IFN- inhibits growth of MCMV in infected macrophages in
a cell-type specific manner via suppression of immediate early protein 1 expression
(Presti et al., 2001). With respect to human herpesviruses, there is evidence to support
the role of NK cells in limiting the early infection of HCMV, a -herpesvirus (Iversen et
al., 2005). However, it remains unclear if NK cells also contribute to the immune control
of gamma-herpes viruses such as EBV although several lines of evidence suggest a role
for innate lymphocytes in the resistance against EBV-associated malignancies. Firstly, in
male patients with X-linked lymphoproliferative disease (XLP), who frequently succumb
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after primary EBV infection to EBV-induced lymphomas, a mutation in the SAP gene
leads to defective recognition of EBV-transformed B cells by NK cells (Benoit et al.,
2000; Morra et al., 2001; Parolini et al., 2000). Secondly, IL-2-activated peripheral blood
NK cells have been shown to restrict EBV-induced B cell transformation in vitro (Kaplan
and Shope, 1985; Masucci et al., 1983; Wilson and Morgan, 2002). Thirdly, NK cell
depletion from PBMCs prior to adoptive transfer into SCID mice, rendered the animals
more susceptible to tumor development after transfer of EBV-transformed B cells
(Baiocchi et al., 2001). Fourthly, activated NK cells have been shown to lyse lytically
EBV replicating B cells

(Pappworth et

al.,

2007).

Fifthly,

a novel primary

immunodeficiency with a specific NK cell defect was recently reported to be associated
with EBV driven lymphoproliferative disease (Eidenschenk et al., 2006). Therefore, NK
cells may be involved in the early phase of the EBV specific immune response.

1.3

Adaptive immune responses against herpes viruses

The innate immune system is effective in combating many pathogens, but it relies on
germ-line encoded receptors for the recognition of conserved structures of the pathogen.
As a consequence, many pathogens have developed strategies to evade recognition
and phagocytosis by the innate immune system. The recognition mechanism used by
the lymphocytes of the adaptive immune response has evolved to overcome the
constraints faced by the innate immune system, and enables recognition of an almost
infinite diversity of antigens, so that each different pathogen can be targeted specifically.
This process of clonal selection and immunological memory has been the basis for the
successful development of vaccines against infectious disease such as polio, influenza,
diphtheria, and tetanus that save millions of lives every year.
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1.3.1

T cell mediated control of herpes virus infection

Herpes viruses have evolved a number of strategies to evade the innate and adaptive
immune response, most strikingly they have the ability to down-regulate viral gene
expression and persist in a latent state in infected host cells (Young and Rickinson,
2004). By limiting viral protein production, they limit the amount of foreign antigen and
infected cells evade recognition by the immune system. However, at the same time
constantly a certain number of infected cells undergo lytic replication leading to the
release of infectious virus and reinfection in vivo posing a constant challenge to the
immune system. Indeed, pathological viral reactivation after immunosuppression of CMV
and EBV sero-positive individuals demonstrate that constant immune surveillance is
necessary to limit viral spread. In the case of EBV, it has been postulated that T cells
constitute the decisive component of EBV specific immune control against virus
associated malignancies, as adoptive transfer of EBV specific T cell lines can eradicate
EBV associated post-transplant lymphomas (Gottschalk et al., 2005; Hislop et al., 2007).
But, it remains unclear which T cell subset is the major contributor responsible for EBV
immune control. Initial longitudinal studies focused on CD8+ T cells since EBV specific
CD8+ T cells are expanded during IM with CD8 T cells specific for lytic or latent antigens
making up to 40 % or 5 % of the CD8+ T cell population, respectively (Callan et al.,
1998)(Figure 4). In contrast, EBV specific CD4+ T cells are not as drastically expanded
as CD8+ T cells, but elevated with frequencies up to 5 % (Amyes et al., 2003). Notably,
as lytic responses decrease over time, LCL specific IFN- secretion by T cells is derived
in equal parts from both CD4+ and CD8+ T cells during persistent infection (BhaduriMcIntosh et al., 2008). In addition to the question about the roles of the T cell subsets, it
is also unknown which T cell specificities are protective during lytic and latent infection.
The CD8+ T cell responses against lytic proteins are clearly focused on IE proteins
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(BZLF1, BRLF1), and on few E proteins, while the CD4+ T cell response seems to be
broader (Adhikary et al., 2006; Precopio et al., 2003; Steven et al., 1997). In the case of
latent infection, different latency patterns confer different degrees of immunogenicity for
recognition by cytotoxic CD8+ and helper CD4+ T cells (Hislop et al., 2007; Khanna and
Burrows, 2000). In healthy EBV carriers, the EBNA3 proteins are the dominant targets of
CD8+ T cell responses, while EBNA1, EBNA2, and EBNA3C are the most consistently
recognized CD4+ T cell. In contrast, the LMPs are subdominant T cell antigens antigens
(Hislop et al., 2007).

1.3.2

CD4+ T cells in immunity against herpes viruses

CD4+ T cells are classically thought to orchestrate adaptive immune responses and it is
widely accepted that CD4+ T cells provide helper functions for antigen-presenting cells
and assist B cells in the production of antibodies. But, studies of MHV-68 have shown
that CD4+ T cells can also directly control infection and its malignant consequences in

vivo, independent of CD8+ T cells and B cells (Robertson et al., 2001). While the
depletion of CD8+ T cells alone resulted in higher virus loads in lung and spleen, the
depletion of both CD4+ and CD8+ T cells leads to a fatal primary infection (Christensen et
al., 1999). In the case of EBV, there is also in vitro evidence that CD4+ T cells control
EBV and EBV-associated malignancies. Depletion of CD4+ T cells from in vitro assays
abolishes immune control of EBV, and addition of CD4+ T cells to T cell–depleted, EBVinfected PBMCs inhibited B cell transformation by EBV more efficiently than unsorted T
cells. Furthermore, CD4+ T cell clones specific for EBNA1 and EBNA2 were found to
inhibit outgrowth of EBV-transformed B cells (Nikiforow et al., 2001; Omiya et al., 2002).
B cell transformation by EBV can also be inhibited by EBV-specific CD4+ T cells derived
from the purified CD4+ T cells of EBV seronegative donors that were primed in vitro by

26

DCs (Bickham et al., 2003). Together these findings show that EBV infection in vitro can
be controlled by virus-specific CD4+ T cells primed in vitro (i.e., a primary response) and
by virus-specific CD4+ memory cells primed in vivo (i.e., a secondary response). It
appears that CD4+ T cells can exert this control directly, independent of CD8+ effector
cells, which suggests that CD4+ T cells can mediate virus-specific immune control as
effectors on their own.
The protective effect CD4+ T cells was classically thought to be mediated via the
secretion of cytokines such as IFN-. IFN- is necessary for the protection of specific
organs in mice against MCMV by CD4+ T cells in vivo, but also for the immune control in
MHV68 (Lucin et al., 1992; Presti et al., 1998). Furthermore, EBV-specific CD4 T cells
have been found to consistently produce IFN-. In addition, it was recently also found
that virus-specific CD4+ T cells can directly kill infected cells. Notably, EBV-specific cells
were among the first CD4+ cytolytic T lymphocytes (CTLs) to be isolated, using LCLs as
targets. These CD4+ CTLs recognized a variety of different EBV proteins expressed in
both latent—EBNA1 (Paludan et al., 2002), EBNA2 (Long et al., 2005), EBNA3C (Long
et al., 2005), and LMP2 (Su et al., 2001)—and lytic—BHRF1 (Landais et al., 2004),
BALF4, and BLLF1 (Adhikary et al., 2006)—stages of EBV infection. Apoptosis induced
by the ligand of the death receptor Fas (FasL) (Nikiforow et al., 2001; Paludan et al.,
2002) and killing by the death effector molecule perforin (Su et al., 2001) were both
identified as cytotoxic mechanisms of EBV-specific CD4+ CTLs. Interestingly, the
EBNA1-specific CD4+ CTLs as well as BLLF1- and BALF4-specific CD4+ CTLs were
found to target Burkitt's lymphoma, an EBV-associated B cell lymphoma which resists
recognition by CD8+ T cells due to down-regulation of the MHC class I antigen
processing machinery. Therefore, particularly in humans where nearly all tissues can
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express MHC class II molecules after immune activation, virus-specific CD4+ CTL could
fill the gap left by viral immune escape from CD8+ CTL recognition.
The presence of CD4+ CTL is neither rare nor exclusive to EBV immunity and to in vitro–
cultured T cell lines. For example, in mice infected with the murine lymphocytic
choriomeningitis virus (LCMV), killing by CD4+ CTLs was observed in vivo after injection
of fluorescent-labeled target cells coated with viral peptides (Jellison et al., 2005). This
LCMV-specific CD4+ T cell cytotoxicity was at least in part due to FasL-induced
apoptosis. In addition, human peripheral blood contains CD4+ T cells that are positive for
the cytotoxic effector molecules perforin and granzyme (Appay et al., 2002) and some
are specific for HCMV. However, while cytotoxic CD4+ T cells have now been reported in

vitro and in vivo, their functional relevance in vivo remains unclear and remains intensely
debated due to its potentially important impact on vaccine development.
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Figure 4: Correlation between viral titers and EBV specific immune responses. Diagrammatic
representation of changes over time in virus replication in the throat and in the load of latently infected B
cells in the blood during acute and convalescent IM, and in the long-term carrier state. Changes in the
magnitude of T cell responses are shown over the same time scale. The effects of T cell suppression on
these parameters of the virus-host balance, as seen in post-transplant patients, are also shown (From
Hislop et al, 2007).

1.4

Animal models to study human-trophic viruses

The use of animal models in the study of human diseases has had obvious advantages.
Fundamental properties of the disease can be investigated more invasively and
thoroughly, while drug and vaccine toxicity and efficacy in animal models can provide
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blueprints for ensuing trials in human subjects, limiting the risk, time and cost of trials in
humans (Ambrose et al., 2007). Hence, researchers have made a considerable effort to
generate animal models for human diseases, and mice are a preferred species for many
avenues of immunological research in vivo. Since the evolutionary divergence of mouse
and man 65 million years ago, however, these two species have inhabited different
ecological niches and have been challenged with minimally overlapping groups of
pathogens. The human and mouse immune systems, evolving to meet these challenges,
have therefore accumulated many differences, making genes related to immunity,
together with genes involved in reproduction and olfaction, the most divergent between
the two species (Mestas and Hughes, 2004; Waterston et al., 2002). Finally and most
importantly, a number of clinically important viruses such as human immunodeficiency
virus (HIV), hepatitis C virus (HCV) and EBV do not infect mice and most other animal
species tested. In the case of HIV, researchers took advantage of the observation that
even though most nonhuman primates are resistant to HIV-1 infection, they do harbor
relatives of the human virus. In fact, the majority of African monkey species are hosts for
various simian immunodeficiency viruses (SIVs). However, in contrast to humans, most
primates can easily live with high virus burdens and they do not usually develop disease.
The host–virus relationship seems to be quite different in these animals, so they cannot
be used as classical animal models of human HIV-1 infection (Ambrose et al., 2007). In
order to overcome the limited availability and high cost of non-human primates
alternative small animal models are desirable to carry out in vivo research without putting
individuals at risk. Humanized mice, or mouse–human chimaeras, have been developed
during the last decades to overcome these constraints and are now an important
research tool for the in vivo study of human cells and tissues (Shultz et al., 2007).
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1.4.1

Humanized mice to study human-trophic virus infection in vivo

Humanized mice can be defined as immunodeficient mice engrafted with human
haematopoietic cells or tissues, or mice that transgenically express human genes. The
development of mice that are humanized by engraftment of human tissues,
haematopoietic stem cells (HSCs) or peripheral-blood mononuclear cells (PBMCs)
provides an opportunity to study human biological processes in vivo that would otherwise
not be possible. Advances in the ability to generate humanized mice have depended on
a systematic progression of genetic modifications to develop immunodeficient host mice
(Shultz et al., 2007).
Three main breakthroughs have occurred generating mouse models suitable to study
longitudinal primary infection with pathogens such as HIV and EBV (Figure 5). First, the
discovery of the Prkdcscid (protein kinase, DNA activated, catalytic polypeptide; severe
combined immunodeficiency, abbreviated scid) mutation in CB17 mice was soon
followed by the observation that human PBMCs, fetal hematopoietic tissues and HSCs
could engraft in these mice (Bosma et al., 1983). However, engraftment occurred at only
a very low level, and the engrafted human cells failed to generate a functional human
immune system. Limitations impeding human-cell engraftment in CB17-scid mice include
the spontaneous generation of mouse T and B cells during aging and high levels of host
NK cell and other innate immune activity, which limit the engraftment of the human
hematopoietic compartment 5. The scid mutation also results in defective DNA repair and,
consequently, an increase in radiosensitivity. Hence, targeted mutations at the
recombination-activating gene 1(Rag1) and Rag2 loci that prevent mature T- and B-cell
development in the mice but have decreased radiosensitivity were developed (Shinkai et
al., 1992). However, these mice retained high levels of NK-cell activity and had limited
engraftment of human HSCs . The second breakthrough was the development of
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immunodeficient non-obese diabetic (NOD)-scid mice (Shultz et al., 1995). Crossing the

scid mutation onto different strain backgrounds led to the observation that NOD-scid
mice supported higher levels of engraftment with human PBMCs than did any of the
other strains that were tested. Furthermore, it was observed that NK-cell activity, which
is one of the main impediments to the engraftment of human hematopoietic cells, was
lower in NOD-scid mice than in CB17-scid mice. NOD-scid mice also have additional
defects in innate immunity that allow higher levels of human PBMC and HSC
engraftment. The third breakthrough was the targeted mutations of the interleukin-2
receptor (IL-2R) -chain locus (Il2r) (DiSanto et al., 1995). These mice support greatly
increased engraftment of human tissue and especially HSCs as well as PBMCs
compared with all previously developed immunodeficient humanized mouse models
(Ishikawa et al., 2005; Ito et al., 2002; Traggiai et al., 2004). The absence of the IL-2R chain leads to severe impairments in T- and B-cell development and function, and
completely prevents NK-cell development. Based on these breakthroughs three different
mouse models have been developed to study functional human immune responses in

vivo. The first one uses BALB/c Rag2-/- c-/- mice, which reconstitute macrophages, T, B,
natural killer, and dendritic cells after neonatal intrahepatic HSC transfer (Gimeno et al.,
2004; Traggiai et al., 2004). The second model reconstitutes NOD-scid c-/- mice by
intravenous injection of human HSCs (Ishikawa et al., 2005), which also leads to
significant development of human myeloid and lymphoid cells. Finally, the most laborintensive model is the BLT mouse, which requires implantation of human fetal liver and
thymus pieces under the NOD-scid mouse kidney capsule in addition to intravenous
HSC injection (Melkus et al., 2006). Immune compartment reconstitution in peripheral
blood of BLT mice is very similar to human.
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Figure 5: The advances in the ability to generate humanized mice have depended on a systematic
progression of genetic modifications to develop immunodeficient host mice. Three main breakthroughs have
occurred in this field. First, the discovery of the Prkdcscid (protein kinase, DNA activated, catalytic
polypeptide; severe combined immunodeficiency, abbreviated scid ) mutation in CB17 mice. The second
breakthrough was the development of immunodeficient non-obese diabetic (NOD)- scid mice. The third
breakthrough was the humanization of immunodeficient mice homozygous for targeted mutations at the
interleukin-2 receptor (IL-2R) -chain locus (from Shultz et al. 2007).

1.4.2

In vivo models for EBV

While

no

similarly

oncogenic

-herpesviruses

of

the

EBV

containing

genus

lymphocryptoviridae (LCVs) has been identified in rodents to date (Ehlers et al., 2008),
priming of immune responses to human (EBV) or closely related monkey LCVs has been
observed after infection in rhesus macaques (Fogg et al., 2006; Fogg et al., 2005),
cottontop tamarins (Wilson et al., 1996). Cottontop tamarins were able to prime MHC
class II restricted CD4+CD8+ T cells with cytotoxicity against EBV transformed B cells
(Wilson et al., 1996). In rhesus macaques, strong cytotoxic and IFN- secreting T cell
responses against the monkey virus homologues of the EBNA1 antigen and the
immediate early lytic EBV antigen BZLF1 were consistently detected in infected animals
(Fogg et al., 2006; Fogg et al., 2005). However, while these animals provide some
insight into the relationship between EBV and the immune system, they are imperfect for
a number of reasons. First, since these monkeys are not natural hosts of EBV, their
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infection and immune response potentially differ significantly from a human immune
response. Second, research that involves monkeys always includes significant ethical
and financial hurdles that make these model systems not suitable for large-scale studies.
First generation mouse models to study EBV infection and EBV-associated malignancies
based on the transfer of human PBMCs into mice carrying the scid mutation (Mosier et
al., 1988). But, these models are limited in its utility due to the relatively low levels of
engraftment and the anergic state of human cells engrafted in the mice (Hesselton et al.,
1993). Injection of larger numbers of human cells to increase levels of cell engraftment
leads to development of EBV-related human lymphoproliferative disorders (LPD) in the
majority of animals (Rowe et al., 1991). Notably, transfer of EBV-specific T cell clones
protected against LPD in this model (Lacerda et al., 1996). In order to improve these
models, PBMCs or CD34+ HSCs were transferred into NOD-scid mice (Islas-Ohlmayer et
al., 2004; Wagar et al., 2000). These early models served as a preclinical model for the
transfer of EBV-specific T cell clones to treat lymphoproliferative diseases and also
offered some insight into the contributions of immune cells to successful immune control
of EBV. However they were not useful to study primary EBV infection and the
development of EBV-specific immune responses. Hence, the lack of an appropriate
animal model of EBV infection prevents assignment of a protective value to the known T
cell specificities, which are required for the design and evaluation of vaccines against
EBV associated tumors and symptomatic primary infection. Therefore, mouse models
that partially reconstitute human immune system components after engraftment of HSC
are of particular interest to study vaccine candidates and EBV specific immune
responses in vivo. In this respect, three novel models of human immune system
reconstitution have been recently described (Ishikawa et al., 2005; Melkus et al., 2006;
Shultz et al., 2005; Traggiai et al., 2004). However, while signs of primary immune
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responses were reported in all three of these current mouse models of human immune
system reconstitution, the protective value of this immunocompetence and, thus, the
potential of these in vivo systems as challenge models for vaccine development against
pathogens with exclusive tropism for humans has not been evaluated.
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2

Material and Methods

2.1

Reagents

2.1.1

Antibodies

Directly labeled monoclonal antibodies for flow cytometry were purchased from BD
Bioscience, Caltag, Biolegend, eBioscience, and Immunotech. Unlabeled monoclonal
antibodies for flow cytometry were purchased from R&D Systems. Secondary antibodies
for flow cytometry were from Molecular Probes. The following monoclonal antibodies
containing no azide / low endotoxin (NA/LE) were used for antibody-mediated blocking:
anti-IL-12 (clone 24910), anti-IL15 (34593, both R&D Systems), anti-IL-18 (125-2H, MBL
International), anti-type I interferon receptor (MMHAR-2, PBL Biomedical Laboratories),
anti-HLA-A/B/C (W6/32, Biolegend), and anti-HLA-DR/DP/DQ(Tü39, BD Biosciences).
IgG1, IgG2a, or IgG2b (NA/LE, Biolegend) were used as isotype control.

2.1.2

Primers

Table 2: Primers for semi-quantitative PCR
Target
Actin
EBNA1
EBNA2
EBER1
LMP1

Primer
5'
3'
5'
3'
5'
3'
5'
3'
5'
3'

Sequence
CAAGAGATGGCCACGGCTGCT
TCCTTCTGCATCCTGTCGGCA
GAGCGTTTGGGAGAGCTGAT
CATTTCCAGGTCCTGTACCT
CATAGAAGAAGAAGAGGATGAAGA
GTAGGGATTCGAGGGAATTACTGA
AAAACATGCGGACCACCAGC
AGGACCTACGCTGGCCCTAGA
AGGTTGAAAACAAAGGAGGTGACCA
GGAACCAGAAGAACCCAAAAGCA

SybrGreen RealTime-PCR
Target
Primer Sequence
GAPDH
5'
AGCCACATCGCTCAGACAC
(transcript)
3'
GCCCAATACGACCAAATCC
HLA-A2
5'
CGGCGCCCGCGGCTCCATCCT
(genomic)
3'
GGGGAGCCCCGCTTCATCGCA
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HLA-DR1
(genomic)
LMP1
(transcript)

5'
3'
5'
3'

GGCCAGTTCTATCTGAATCC
CGTCTCCTTCTTTGCCATATCCA
AGGTTGAAAACAAAGGAGGTGACCA
GGAACCAGAAGAACCCAAAAGCA

Table 3: Primer for Taqman RealTime-PCR
Target
EBV BamHI
W fragment
(genomic)
Bcl2
(genomic)
BZLF1
(transcript,
B95.8))
EBNA1
(transcript)
EBNA2
(transcript)
LMP1
(transcript)
LMP2A+B
(transcript)
LMP2A
(transcript)
LMP2B
(transcript)

2.2
2.2.1

Primer
5'
3'
Probe
5'
3'
Probe
5'
3'
Probe
5'
3'
Probe
5'
3'
Probe
5'
3'
Probe
5'
3'
Probe
5'
3'
Probe
5'
3'
Probe

Sequence
GGACCACTGCCCCTGGTAA
TTTGTGTGGACTCCTGGGG
TCCTGCAGCTATTTCTGGTCGCATCA
CCTGCCCTCCTTCCGC
TGCATTTCAGGAAGACCCTGA
CTTTCTCATGGCTGTCC
ACGCACACGGAAACCACA
CGCTTTATTTCTAGTTCAGAATCGC
FAM-CAGCCAGAATCGCTGGAGGAA-BHQ-1
GATCAGGGCCAAGACATAGAGATG
CCTTTGCAGCCAATGCAACT
FAM-TGTCCGGAGACCCCAAAAACG-BHQ-1
GGGATGCCTGGACACAAGAG
CATGCCCGACGTCATATCCT
FAM-CATCACCTCTTGATAGGGATCCGC-BHQ-1
TGGAGCCCTTTGTATACTCCT
TGCCTGTCCGTGCAAATTC
FAM-TGATCACCCTCCTGCTCATCGCTCT-BHQ-1
TGCCTGGATTCTTACAGCAGG
GGCAGCATCTAATGACCCCA
FAM-CCTGATTTTCCTCATTGGCTTTGCCCT-BHQ1
CGGGATGACTCATCTCAACACA
CAATTACAGGCAGGCATACTGG
FAM-ATACGAAGAAGCGGGCAGAGGAAGTATGAA-BHQ1
GCAGTGTAATCTGCACAAA
CAATTACAGGCAGGCATACTGG
FAM-TGGCGGCAGGCGGGAGGCCGTGCTTTA-BHQ1

Primary cells and cell lines
Human tonsils, lymph nodes and spleens

All tonsils, lymph nodes and spleens were obtained as part of Institutional Review
Board-approved protocols. Tonsils were collected immediately after surgery from
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patients undergoing tonsilectomy for chronic inflammation. Tonsils were not acutely
inflamed at the time of removal. Spleens and lymph nodes were procured by the regional
Organ Procurement Organization from brain-dead donors after obtaining informed
consent from appropriate individuals. Soon after their removal, tissues were
mechanically dissociated to obtain single cell suspensions and were then filtered through
a 75-μm nylon cell strainer to exclude undissociated fragments. Debris and dead cells
were eliminated by density-gradient centrifugation on Ficoll/Hypaque. Single cell
suspensions were then extensively washed and cryopreserved.
2.2.2

Preparation of DCs

PBMCs were isolated from leukocyte concentrates (New York Blood Center) by densitygradient centrifugation on Ficoll/Hypaque. CD14+ cells were isolated from PBMCs by
positive magnetic cell separation (MACS, Miltenyi Biotec) and cultured for 5 days in
RPMI1640 + 1% single donor plasma + IL-4 and GM-CSF according to standard
protocols (Ferlazzo et al., 2004a). The CD14- cells were frozen for later isolation of B
cells and NK cells. Splenic DCs were isolated as previously described by flow cytometric
sorting using a BD FACSVantage SE cell sorter (Ferlazzo et al., 2004a). To isolate
CD11c+ cells from blood, PBMCs were overlayed with an Optiprep gradient (1.080 to
1.049) and centrifuged for 30 min at 700xg. Low-density fractions were collected and
CD11c+ DC were further enriched by depletion of CD14+, CD3+, CD8+, and CD19+ cells
by MACS. CD11c+ DCs were purified by flow cytometric sorting using a BD FACS Aria
cell sorter by isolating lineage negative (CD3, CD14, CD19, and CD56), HLA-DR+, and
CD11c+ cells. Purify after sorting was regularly higher than 99.5%. Monocyte-derived
DCs were matured for 2d in medium with IL-4, GM-CSF, and i) 10 ng/ml IL-1, 1,000
units/ml IL-6, 10 ng/ml TNF-, and 1 μg/ml prostaglandin E2 (cyt DC), ii) 25 μg/ml
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polyinosine-polycytidylic acid (poly(I:C), Invivogen) (poly(I:C) DC), iii) 25 ng/ml IL-1, 50
ng/ml TNF-, 3,000 IU/ml IFN-, 500 pg/ml IFN-, and 25 μg/ml poly(I:C) (DC1), iv) 250
ng/ml LPS (Sigma) (lps DC). CD11c+ DCs were exposed to AGS-cell derived EBV at an
MOI of 1. Maturation of DCs was monitored by flow cytometry using anti-CD25, antiCD80, anti-CD83, anti-CD86, and anti-HLA-DR antibodies. Secretion of cytokines was
quantified using IL-12p70 ELISA, IL-15 ELISA (both R&D Systems) and IL-18 ELISA
(Bender Medsystems).

2.2.3

Isolation of B cells and NK cells

Frozen CD14- PBMCs were thawed, washed and B cells were isolated by positive
selection using CD19-Microbeads (Miltenyi Biotec). NK cells were isolated from either
CD19- or CD14- fractions by negative selection using the NK cell Isolation Kit II (Miltenyi
Biotec) according to the manufacturers instructions. The purity of the isolated B cells
and NK cells was higher than 90% and contained less than 5% contaminating T cells as
determined by flow cytometry. For other experiments, B cells, NK cells, and NK cell
subsets were isolated by flow cytometric sorting using a BD FACSVantage SE cell
sorter.

2.2.4

Isolation of CD34+ cells from fetal livers

Human fetal liver was obtained from Advanced Bioscience Resources as part of an
Institutional Review Board-approved protocol. The tissue was minced and treated with 2
mg/ml collagenase D (Roche Diagnostics) in HBSS with CaCl2/MgCl2 for 30 minutes at
RT followed by filtering through 70 μm nylon cell strainers (BD Biosciences).
Mononuclear cells were isolated by density-gradient centrifugation on Ficoll/Hypaque.
CD34+ human hematopoietic stem cells (HSCs) were isolated using the Direct CD34
Progenitor Cell Isolation Kit (Miltenyi Biotec).
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2.2.5

Isolation of mononuclear cells and CD34+ cells from cord blood

Cord blood was obtained as part of Institutional Review Board-approved protocols from
the New York Blood Center. Cord blood was processed within 16 h after birth to secure
viability of cells. Cord Blood was diluted 1:4 with PBS and mononuclear cells (CBMCs)
were isolated by density-gradient centrifugation on Ficoll/Hypaque. CD34+ human
hematopoietic stem cells (HSCs) were isolated using the Direct CD34 Progenitor Cell
Isolation Kit (Miltenyi Biotec).

2.2.6

Cell lines

Table 4: Cell Lines
Name

Source

Medium

AGS

ATCC

AGS/EBV

L. Hutt-Fletcher

B95-8
CEM
Daudi
K562
LCL721.221
OKT4
OKT8
Raji

ATCC
ATCC
ATCC
ATCC
ATCC
ATCC
ATCC
ATCC

F12 + 10 % FCS
F12 + 10 % FCS
+ 500 mg G418
RPMI + 10 % FCS
RPMI + 10 % FCS
RPMI + 10 % FCS
RPMI + 10 % FCS
RPMI + 10 % FCS
DMEM+ 10 % FCS
RPMI + 10 % FCS
RPMI + 10 % FCS

2.3

Mouse Strains

Rag2-/-c-/- mice were kindly provided by Hergen Spits (UMC Amsterdam, Netherlands).
NOD/LtSz-scid IL2Rnull (NSG) mice were obtained from The Jackson Laboratory (Bar
Harbor, ME). NOD/LtSz-scid IL2Rnull HLA-A2 transgenic (NSG-A2) mice were kindly
provided by Gloria Koo (Memorial Sloan Kettering Cancer Center). All mice were raised
under specific pathogen free conditions.
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2.4
2.4.1

Experimental procedures
Generation of EBV-derived dsRNA

A 1.3 kB fragment spanning the coding region of LMP1 in one direction and part of the
first intron of LMP2A in the other direction was cloned into pGEM (Promega) between
the T7 and SP6 promoter. ssRNA was generated using linearized plasmid and the
Riboprobe Combination System SP6/T7 (Promega). After verification of integrity of RNA
by gel electrophoresis, ssRNA was purified using RNeasy Kit (Qiagen) and quantified by
Nanodrop. Finally, equal amounts were annealed in siRNA buffer (Dharmacon) to
generate dsRNA and successful annealing was confirmed by gel electrophoresis.

2.4.2

Quantification of gene expression

2.4.2.1 Quantification of gene expression by semi-quantitative one-step RT-PCR
RNA was isolated from non-treated and IFN--treated B cells infected with EBV at
indicated time point using the RNeasy Kit (Qiagen) according to the manufacturers
instructions. 10 ng of total RNA were used for semi-quantitative RT-PCR using the
OneStep RT-PCR-Kit (Qiagen) and gene-specific primers using the following program:
50°C (30 min), 95°C (15 min), followed by an increasing number of cycles of 95°C (30
sec), 55°C (30 sec), and 72°C (30 sec). Primers sequences are detailed in section 2.1.2.
The lowest cycle number for which a band was detected on an agarose gel was used to
quantify the mRNA level.
2.4.2.2 Quantification of gene expression by semi-quantitative two-step RT-PCR
To generate cDNA for RealTime-PCR, total RNA was reverse transcribed using the
TaqMan Reverse Transcription Reagent (Applied Biosystems), using the following
program: 25°C (10 min), followed by 50°C (30 min) and 75°C (5 min sec). If SybrGreen
was used to detect amplification of specific cDNA, amplification was performed using

41

cDNA from the reversed transcribed reaction, primer mixture (0.25 μM each of sense
and antisense primers), and 1x SYBR Green Master Mix (Applied Biosystems). If genespecific Taqman probes were used to detect amplification of specific cDNA, amplification
was performed using cDNA from the reversed transcribed reaction, primer mixture (0.3
μM each of sense and antisense primers), gene-specific probe (0.25 μM) and 1x
Taqman Master Mix (Applied Biosystems). PCR was performed in ABI 7900HT (Applied
Biosystems) using following program: 50°C (2 min), 95°C (10 min), followed by 40 cycles
of 95°C (15 sec), and 60°C (1 min). The final mRNA levels of EBV-encoded genes was
normalized to GAPDH using the comparative CT method. Primers sequences for
RealTime-PCR are detailed in section 2.2.

2.4.3

Quantification of EBV viral loads by quantitative Real-time-PCR

Splenic EBV viral DNA load was quantified by Real-time PCR. DNA was extracted using
the Tissue and Blood DNA kit (Qiagen) or the Wizard SV Genomic DNA purification
system (Promega). following the manufacturer's protocol. A region from the BamHI W
fragment of EBV and the human bcl-2 gene was amplified using primers detailed in
section 2.1.2. Amplification was performed using 500 ng DNA, primer mixture (0.3 μM
each of sense and antisense primers), gene-specific probe (0.25 μM) and 1x Taqman
Master Mix (Applied Biosystems). PCR was performed in ABI 7900HT (Applied
Biosystems) using following program: 50°C (2 min), 95°C (10 min), followed by 40 cycles
of 95°C (15 sec), and 60°C (1 min). Plasmid DNA containing either region were diluted
and used as standard. The EBV BamHI W fragment copy number per cell was calculated
using the formula N = 2 x W/ B, where N is the EBV BamHI W copy number/cell, W is the
EBV BamHI W copy number and B is the bcl-2 copy number. All samples were tested in
triplicates.
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2.4.4

Mouse genotyping by RealTime-PCR

DNA was isolated from ~3mm long pieces of tail. These pieces were digested in 200 ul
50 mM NaOH at 98 C for 1 hour, and the reaction was neutralized by adding 20 ul of 1M
Tris HCl pH 8. Crude extracts were then spun at 4000 rpm for 3 minutes in a table top
centrifuge and supernatants transferred to fresh tubes. 1 μl of DNA was used in a 25 μl
reaction with the respective primer mixture (0.25 μM each of sense and antisense
primers), and 1x SYBR Green Master Mix (Applied Biosystems). PCR was performed in
ABI 7900HT (Applied Biosystems) using following program: 50°C (2 min), 95°C (10 min),
followed by 40 cycles of 95°C (15 sec), and 60°C (1 min).

2.4.5

Tetramer production and purification

Tetrameric HLA-A2/peptide and HLA-B8/peptide complexes were generated as
previously described (Busch et al., 1998). Recombinant proteins were generated
separately from insoluble proteins trapped in inclusion bodies following induction with
IPTG in E. coli strain BL21 (DE3). Inclusion bodies containing HLA-A2, HLA-B8 and
2m, respectively, were dissolved in 8 M urea and stored at -80 C. For refolding, HLA-A2
or HLA-B8 was added to the respective peptide and protease inhibitors (1 g/ml
pepstatin, 1 g/ml leupeptin) to stabilize monomeric HLA/peptide complexes.
Subsequently, these were purified by gel filtration over a Superdex 200 HR column (GE
Healthcare) and in vitro biotinylated for 12 hr at 20°C in the presence of 15 g BirA
(Avidity), 80 M biotin, 10 mM ATP,10 mM MgOAc, 20 mM bicine, and 10 mM Tris-HCl
(pH 8.3). To remove free biotin, monomeric complexes were again purified by gel
filtration, and then tetramerized by addition of PE–labeled Extravidin (Sigma) at a molar
ratio of 4:1.
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2.4.6

Antibody production and purification

Antibody was produced in RMPI or DMEM, respectively, supplemented with 10% Ultralow IgG FCS + gentamycin and purified using an Äktapurifier 10 and HiTrap Protein A
HP columns. Antibodies were eluted using 0.1 M citrate buffer and the eluate was
immediately neutralized with 1 M Tris /HCl, pH 8.0. Then, the antibody was desalted
against PBS using HiTrap Desalting columns. The purity of the antibody was at least 95
% as determined by Coomassie stain. If necessary endotoxins were removed using
Endotrap Blue columns and the final antibody preparations contained less than 0.1
EU/ml endotoxins as measured by LAL test (Cambrex Corporation).

2.4.7

Preparation of EBV

2.4.7.1 Preparation of EBV from B95.8 cells
The EBV+ marmorset cell line B95-8 was seeded at 2x 105 cells / ml and cultured for 12
d in RPMI1640 + 10% FCS + gentamycin without refeeding. Virus-containing
supernatant was centrifuged at 2000 rpm for 10 min and passed through a 0.45 μm filter.

2.4.7.2 Preparation of EBV from AGS cells
EBV+ AGS cells were used to produce EBV as previously described (Borza and HuttFletcher, 2002). Briefly, EBV lytic cycle was induced in EBV-positive AGS cells by
addition of PMA and sodium butyrate. EBV was further purified by ultracentrifugation
over a 25 % sucrose step gradient and subsequently titered on Raji cells. GFP+ cells
were counted 2 days later and titers calculated in Raji-infecting units. AGS-derived EBV
preparations contained less than 0.1 EU/ml endotoxins as measured by LAL test
(Cambrex Corporation).
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2.4.8

Proliferation assay

Isolated NK cells, or B cells were labeled with 0.5 μM CFSE in PBS for 10 min at 37°C.
After washing twice with RPMI1640 + 5% human serum + gentamycin, cells were
counted and used for culture. Typically, NK cells (2.5 x 105 cells in 96 well plate) were
cultured with 500 IU/ml IL-2 or autologous DCs at a ratio of 5:1 for 6 days at 37°C in
RPMI1640 + 5% human serum + gentamycin. In selected experiments, isotype control
antibody (5 μg/ml) or blocking antibodies against IL-12, IL-15 (5 μg/ml each), and IL-18
(1 μg/ml) were added to the cultures at the beginning and on day 3 of culture. Where
indicated, DCs (bottom) were separated from NK cells (top) by 0.4 μm pore membranes
(Corning). CFSE fluorescence and CD16 staining was evaluated on CD3-CD56+ cells by
flow cytometry. Where indicated, B cells were CFSE labeled as described above and
proliferation of CD19+CD20+ cells was evaluated with and without 10,000 pg/ml IFN-
addition after infection with EBV as CFSE dilution by flow cytometry. Live cell numbers
were determined by trypan blue exclusion.

2.4.9

Detection of IFN- secretion by intra-cellular cytokine staining

For intracellular staining of IFN-, isolated NK cells from blood (2.5 x 105 cells in 96 well
plate) were incubated with 500 IU/ml IL-2 or autologous DCs at a ratio of 1:2 at 37°C in
RPMI1640 + 5% human serum + gentamycin. In selected experiments, isotype control
antibody (5 μg/ml) or blocking antibodies against IL-12, IL-15 (5 μg/ml each), and IL-18
(1 μg/ml) were added. Brefeldin-A was added after 6 h of co-culture and additional 6 h
later cells were harvested and stained with anti-CD3, anti-CD56 and anti-CD16. After
fixing the cells with 2 % paraformaldehyde, they were permeabilized and stained with
anti-IFN-.
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2.4.10 Detection of IFN- secretion by ELISA
IFN- was detected in cell culture supernatants or mouse plasma using a commercial
ELISA (Mabtech). For NK/DC co-culture experiments, NK cells and DCs were cultured
direcly together at a ratio of 5:1 or DCs (bottom) were separated from NK cells (top) by
0.4 μm pore membranes and IFN- production was measured after 20h. To directly
compare IFN- production, sorted NK cell subsets from blood, spleen, tonsil and lymph
node (1 x 104 cells CD56brightCD16-, 1 x 105 CD56+CD16+) were then cultured with
allogeneic or autologous DCs at a ratio of 1:10 or 1:1, respectively and after 20 h IFN-
levels were determined using ELISA.

2.4.11 Analysis of EBV-specific T cell responses by IFN- ELISPOT
EBV-specific T cell responses were analyzed using an IFN- ELISPOT as previously
described (Munz et al., 2000). Briefly, splenocytes were depleted of human CD19+ cells
and mouse CD45+ using anti-CD19 and anti-CD45 microbeads (Miltenyi Biotec). The
negative fraction after the depletion was stimulated with autologous LCLs at a ratio of 1:4
for 18 hrs. Spots were counted with an ELISPOT reader (Autoimmun Diagnostika GmbH,
Germany). In blocking experiments, LCL recognition by T cells was blocked by
preincubation of the target cells with 10 μg/ml anti-HLA-A/B/C, anti-HLA-DR/DP/DQ and
combination thereof, respectively.

2.4.12 Degranulation assay
To characterize the multifunctionality of EBV-specific clones, T cell clones were
stimulated at an effector to target ratio of 5:1 with autologous LCLs for 6 hrs in the
presence of anti-CD107 antibody. Similarly, IFN- secretion and cytotoxicity of NK cells
in bulk PBMCs, CBMNCs, or splenocytes was measured by coculturing them with target
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cells at an effector to target ratio of 10:1. To detect spontaneous degranulation and
cytokine production, a control without target cells was included. After 1 hrs, monensin
(Sigma-Aldrich, 1μg/ml) was added to all samples. At the end of the incubation, cells
were stained with antibodies against surface antigens, and then they were fixed,
permeabilized, and stained with an anti-IFN- antibody. Samples were finally analyzed
by flow cytometry.

2.4.13 Cytotoxicity assay
To evaluate the cytolytic activity of NK cells, following NK cell-sensitive cell lines were
used as target cells: LCL721.221, K562, and CCRF-CEM. The cytolytic activity of T cell
clones was measured against the autologous LCL. Cytotoxicity assays were performed,
as previously described (Ferlazzo et al., 2004b). Briefly, target cells were labeled with
PKH26 (Sigma-Aldrich, St. Louis, MO), and then incubated with effector cells at different
effector cell/target ratios. After 6 h, cells were harvested; TO-PRO-3, a membraneimpermeable DNA stain, was added to each culture (1 μM final concentration); and cells
were finally analyzed by flow cytometry. Background and maximum TO-PRO-3 staining
were obtained by incubation of target cells with medium and detergent, respectively. The
percent specific lysis was calculated as (% TO-PRO-3+PKH26+ cells in efector/target cell
co-culture

- % TO-PRO-3+PKH26+ cells in medium)/( % TO-PRO-3+PKH26+ cells in

detergent - % TO-PRO-3+PKH26+ cells in medium) x 100%.

2.4.14 B cell transformation assay with peripheral blood, splenic and tonsillar
mononuclear cells
Isolated B cells (1 x 105 cells in 48 well plate) were cultured in RPMI1640 + 5% human
serum + gentamycin, infected with EBV and isolated NK cells were added at indicated
numbers. In experiments including DCs, they were added at B cell to DC ratios of 1:1. In
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other experiments, B cells and DCs (bottom) were separated from NK cells (top) by 0.4
μm porous membranes. After 12 d, numbers of transformed B cells were quantified by
counting live cells

via

trypan

blue exclusion

and

determining the

ratio of

CD19+CD21+CD23+ cells to total live cells by flow cytometry. Restriction of B cell
transformation was calculated by comparing numbers of transformed B cells between
respective samples with and without NK cells; % Restriction of B cell transformation = (1
– total transformed B cell number of sample with NK cells / total transformed B cell
number of sample without NK cells ) x 100.

2.4.15 B cell transformation assay with bulk tonsillar mononuclear cells
Cryopreserved tonsillar mononuclear cells were thawed, washed, and then stained with
anti-CD3 and anti-CD56. Cells were then depleted i) of CD3+ cells (Tonsil -T) or ii) of
CD3+ and CD56+ cells (Tonsil -NK-T) by flow cytometric sorting using a BD
FACSVantage SE cell sorter. The number of sorted cells per condition was adjusted
according to the ratio between sorted cells and input cell numbers (1 x 106 cells in 48
well plate). Then, the cells were infected with EBV and, where indicated, DCs were
added at ratio of total cell to DC of 10:1. After 12 d, numbers of transformed B cells were
quantified by counting live cells via trypan blue exclusion and determining the ratio of
CD19+CD21+CD23+ cells to total live cells by flow cytometry. Restriction of B cell
transformation was calculated by comparing numbers of transformed B cells between
respective samples with and without NK cells; % Restriction of B cell transformation = (1
– total transformed B cell number of sample with NK cells / total transformed B cell
number of sample without NK cells) x 100.
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2.4.16 Cloning of antigen-specific T cells
Splenocytes or PBMCs were then labeled with 0.5 μM CFSE (Invitrogen, CA), and
cultured in complete medium containing a single peptide (1 μM), libraries of EBV
peptides (1 μM each) or autologous irradiated LCLs at a ratio of 5:1, respectively. On
day 6, CFSElow CD3+ cells were sorted by flow cytometry and cloned by classical limiting
dilution. Briefly, 10, 1, 0.3 cells were plated per well of a 96 well plate in RPMI + 8 %
human serum + gentamycin containing 150 U/ml IL-2 and 1 μg/ml PHA. After initial
expansion, individual clones were screened by IFN--ELISPOT after restimulation with
the cognate peptides or autologous irradiated LCLs, respectively. Individual clones that
recognized one of the libraries were further tested against a matrix of peptide sub-pools
to identify the specific peptides.

2.4.17 Preparation of humanized mice
2-5 days old NSG mice were irradiated with 100 cGy and injected intra-hepatically with
1-3 x 105 CD34+ HSCs 6 hrs post irradiation. The mice were bled 10-12 weeks post
engraftment and peripheral lymphocytes were analyzed by FACS to check for the
reconstitution of the human immune system.

2.4.18 EBV infection of mice and in vivo depletion of T cells
Reconstituted mice were infected with EBV at different infectious doses ranging from 105
to 106 Raji-infecting units by intra-peritoneal injection. In selected experiments, human
CD4+ and CD8+ T cells cells were depleted prior to EBV infection by intra-peritoneal
injection of 100 μg OKT-4 and 100 μg OKT-8 on three consecutive days. In order to
deplete T cells for the duration of the experiment, the same injection regimen was
repeated two weeks later.
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2.4.19 Microscopically analysis of tissues
Immunohistochemical stainings were performed on formalin-fixed, paraffin-embedded
tissue sections by Amy Chadburn and Yi-Fang Liu from Weill Medical College. The
antibodies used included anti-CD20 (clone L26), anti-CD8 (clone C8/144B), anti-CD68
(clone PGM1), anti-EBNA2 (clone PE2), anti-LMP1 (clone CS1-4; DAKO Cytomation,
Denmark), anti-CD3 (clone SP7, Thermo Fisher Scientific, CA), anti-CD21 (clone 2G9)
and anti-CD56 (ERIC-1; Novocastra, UK). In situ hybridization for Epstein Barr virus was
performed

using

an

EBER

probe

(Vision

Biosystems,

Australia).

Double

immunohistochemical staining and dual in situ hybridization with immunohistochemical
staining was performed using the Bond Max Autostainer (Leica Microsystems).
Formalin-fixed, paraffin-embedded tissue sections were deparaffinized and endogenous
peroxidase was inactivated. For the first antibody, antigen retrieval was performed using
either the Bond Epitope Retrieval Solution 1 (ER1) or the Bond Epitope Retrieval
Solution 2 (ER2) at 99-100oC for 20-30 minutes. Following retrieval, the sections were
incubated sequentially with the primary antibody for 25 minutes, post-primary for 15
minutes and polymer for 25 minutes (Bond Polymer Detection System; Vision
Biosystems) followed by colorimetric development with diaminobenzidine (DAB; Vision
Biosystems). For the subsequent staining with the second antibody, the sections were
heated in Bond Epitope Retrieval solution (either ER1 or ER2) at 99-100oC for 20-30
minutes followed by blocking of endogenous alkaline phosphatase using Dual
Endogenous Enzyme Block (DAKO Cytomation). The sections were then sequentially
incubated with the second primary antibody, biotinylated link and streptavidin-AP (LSAB
2 System-AP; DAKO Cytomation) for 25 minutes, 15 minutes and 30 minutes,
respectively, followed by red chromagen development with permanent red (DAKO
Cytomation). With respect to dual in situ hybridization – immunohistochemistry, in situ
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hybridization was performed first according to the manufacturers instructions (Vision
Biosystems) with colorimetric development using DAB followed by immunostaining as
described for the second antibody. Single immunohistochemical staining was performed
as described for the first primary antibody above.

2.4.20 Statistical analysis
Statistical analyses were performed with the paired two-tailed Student t-test or the MannWhitney test as indicated. The p value of significant differences is reported. Plotted data
represent mean plus standard deviation (SD), unless otherwise stated.
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3

Results

3.1
3.1.1

The role of NK cells during primary EBV infection
NK cell activation by differently matured DCs.

The outcome of the crosstalk between NK cells and DCs depends strongly on the
activation status of both cell types. In order to define the optimal activation conditions for
anti-viral NK cell responses, differently matured human monocyte-derived DCs were
tested for their capacity to elicit proliferation and IFN- secretion by NK cells. DCs were
matured using a standard mixture of proinflammatory cytokines (IL-1, IL-6, TNF- and
PGE2: cyt DC), the TLR3 and mda-5 ligand poly(I:C) (poly(I:C) DC), and the TLR4 ligand
LPS (lps DC). In addition, DCs were matured with poly I:C supplemented with
proinflammatory cytokines (IL-1 and TNF-) and type I and II interferons (DC1) to
generate DC1 cells according to Mailliard and colleagues (Mailliard et al., 2004). As
expected, all of these maturation stimuli were able to significantly up-regulate MHC class
II and costimulatory molecules such as CD80, CD83 and CD86 (Table 4). However,
when we compared different DC preparations for their capacity to activate NK cells from
peripheral blood, we found that DCs matured with poly(I:C) were far superior in NK cell
activation compared to the other DC preparations (Figure 6). poly(I:C) DCs and DC1s
induced strong proliferation with 40-75% of the NK cells cycling after 6 days. Further
characterization showed that the number of NK cells producing IFN- increased
significantly (4-fold to 10-fold), when they were activated by poly(I:C) DCs and DC1s
compared to immature DCs (iDCs) or cyt DCs, respectively (Figure 6). In line with
previous findings, the CD56brightCD16- NK cells were preferentially stimulated by these
DC preparations to proliferate and secrete IFN- (Figure 6). These data demonstrate that
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DCs matured by poly(I:C) are efficient stimulators of CD56brightC16- NK cells, the NK cell
subset enriched in human secondary lymphoid tissues.

Figure 6: DCs activate NK cells most efficiently after maturation with the dsRNA analog poly(I:C).
Differently matured DCs were compared to immature DCs for their ability to induce NK cell proliferation (A)
and IFN- secretion (B). The tested maturation stimuli included i) the standard proinflammatory cytokine
cocktail consisting of IL-1, IL-6, TNF-, and prostaglandin E2 (cyt DC), ii) the TLR3 and mda-5 agonist
poly(I:C) (poly(I:C) DC), iii) a cocktail of inflammatory cytokines (IL-1, TNF-), IFN-, IFN-, and poly(I:C)
(DC1), iv) the TLR4 agonist LPS (lps DC). (A) CFSE-labeled NK cells and DCs were cultured for 6d at a ratio
of 5:1 and proliferation was analyzed by gating on CD3-CD56+ cells. Percentages of CFSE dilute CD16+ and
CD16- NK cells are indicated. (B) NK cells and DCs were cultured for 20 h at a ratio of 2:1 and BFA was
added for the last 8 h. IFN- production of CD3-CD56+ cells was analyzed. Percentages of IFN- positive NK
cells are indicated. Similar results were obtained in three independent experiments.
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Table 5: Surface expression of DC maturation markers on monocyte-derived DCs
Maturation
HLA-DR
stimulus

CD25

CD80

CD83

CD86

IL-15R

none
307a
87
301
104
412
4
cyt
435
265
546
407
690
15
poly(I:C)
429
267
602
390
745
37
DC1
429
347
620
412
742
68
LPS
403
269
558
429
671
20
dsRNA
354
205
450
167
621
8
a
: Values indicate mean flourescence intensities (substracted from isotype
control staining)
Similar results were obtained in at least four experiments

3.1.2

IL-15
21
62
75
72
52
23

Production of NK cell stimulatory cytokines upon DC maturation with viral
stimuli.

To characterize the mechanism of DC-mediated NK cell activation, we compared the
production of NK cell stimulatory cytokines by DCs after maturation. Previous work
indicated important roles for IL-12, IL-15, and IL-18 in the activation of NK cell
proliferation and IFN- secretion. We detected only little (< 50 pg/ml) or no secretion of
the bioactive form of IL-12 (IL-12p70) by cyt DCs or iDCs, respectively, whereas
poly(I:C) DCs and DC1s produced high amounts of this cytokine (up to 5000 pg/ml)
(Table 6). LPS-matured DCs produced intermediate amounts of IL-12p70. Monocytederived DCs matured with EBV-derived dsRNA produced slightly higher IL-12 levels than
LPS matured DCs (up to 200pg/ml). The addition of recombinant IL-12p70 at
comparable levels ( 100pg/ml) induced both proliferation and IFN- production by NK
cells (data not shown). IL-15 secretion and surface expression of IL-15 and IL-15R
were also primarily induced by incubation of DCs with poly(I:C) (Table 5, Table 6). IL-18
secretion was not detectable for all DC preparations tested (Table 5). In line with these
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observations, IFN- secretion of NK cells stimulated by DC1s was mainly dependent on
IL-12 (80 %, p < 0.01) and to a lesser degree on IL-18 (15%, p < 0.05) (Figure 7). Similar
results were obtained with poly(I:C) DCs (data not shown). Consistent with the
hypothesis that poly(I:C)-matured DCs mainly elicited IFN- secretion of NK cells via
their high levels of secreted IL-12, this NK cell/DC interaction was not sensitive to
transwell separation (Figure 7B). Furthermore, we found that NK cell proliferation upon
co-culture with DC1s (Figure 7C) and poly(I:C) DCs (data not shown) could be blocked
with an IL-12 specific antibody by 90% or 80%, respectively (p < 0.01 for both), and
again transwell experiments showed that direct cell contact was not required (data not
shown). Blocking of IL-15 also significantly decreased numbers of surviving NK cells
when combined with anti-IL-12 antibodies (p < 0.01), however blocking of IL-15 or IL-18
alone did not significantly decrease survival (Figure 7D). In addition, antibody blocking of
IL-2 did not influence DC induced proliferation and IFN- production by NK cells (Figure
8). These data suggest that poly(I:C), and EBV-derived dsRNA elicit IL-12 production,
which in turn stimulates NK cell proliferation and IFN- production by NK cells.

Table 6: Secretion of IL-12, IL-15, and IL-18 by DCs
Maturation stimulus

IL-120

IL-15a

IL-18a

none

<16.25b

12 ± 11

40 ± 32

cyt

29 ± 25

78 ± 40

55 ± 23

poly(I:C)

2445 ± 985

159 ± 68

44 ± 11

4123 ± 1098 289 ± 84

50 ± 19

DC1
LPS

69 ± 40

n.d.

n.d.

dsRNA

85 ± 35

n.d.

n.d.

a

: Samples were 10-fold concentrated

b

: Values indicate concentration of cytokine in pg/ml

n.d.: not determined
Results represent data from 6 experiments
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Figure 7: NK activation by poly(I:C)-matured DCs is IL-12 dependent and is mainly restricted to
CD56brightCD16- NK cells. (A) Blood NK cells were activated by DC1s in the presence or absence of
blocking antibodies and IFN- production of CD3-CD56+ cells was assayed by intracellular cytokine staining.
Percentages of IFN- positive NK cells are indicated. (B) NK cells were cultured directly or separated by
transwell with DC1s. In addition, cytokines were blocked in transwell experiments using blocking antibodies.
IFN- levels were measured by ELISA (mean ±s.d.) (C) NK cells were cultured with DC1s in the presence or
absence of blocking antibodies for 6 d and CFSE dilution of CD3-CD56+ cells was analyzed. Percentages of
CFSE dilute CD16+and CD16- NK cells are indicated. (D) After 6 d of NK cell-DC co-cultures, live cells were
counted and subsequently, numbers of total and surviving CD3-CD56+ NK cells were determined by
measuring ratios of total and proliferating NK cells of total live cells. Data represents numbers of proliferating
and total NK cells compared to controls without antibody blocking (mean ±s.d.). Mouse-IgG1 was used in all
experiments as isotype control. Data in (A)-(D) represent results of at least three independent experiments.
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Figure 8: IL-2 is not responsible for DC1 induced NK cell proliferation and IFN- production. (A) NK
cells were cultured with iDCs or DC1s in the presence or absence of blocking antibodies for 6 d and CFSE
dilution of CD3-CD56+ cells was analyzed. Percentages of CFSE-dilute NK cells are indicated. (B) After 6 d
of NK cell-DC co-cultures, live cells were counted and subsequently, numbers of total and surviving CD3CD56+ NK cells were determined by measuring ratios of total and proliferating NK cells of total live cells.
Data represents numbers of proliferating and total NK cells compared to DC1 co-culture without antibody
blocking (mean ± s.d.). Data in (A) and (B) represent results of three independent experiments. (C) Sorted
NK cell subsets were cultured with medium, IL-2 (500 U/ml) or DC1s in the presence or absence of blocking
antibodies for 20 h and IFN-g was analyzed by ELISA. Data in (C) represent results of two independent
experiments done in duplicates (mean ± s.d.). Mouse-IgG1 was used in all experiments as isotype control.
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3.1.3

Restriction of EBV-induced B cell transformation by NK cells upon
activation by poly(I:C) matured DCs.

In contrast to previous studies focusing on IL-2 activation of NK cells, we addressed the
question whether NK cells restrict EBV-induced B cell transformation after activation by
cells of the innate immune system. Because interactions between NK cells and DCs
have been shown to be essential for virus control in murine models of herpes virus
infections (Andrews et al., 2003; Kassim et al., 2006; Orange et al., 1995), we
specifically investigated whether DCs can activate NK cells to limit EBV-mediated B cell
transformation. For these experiments we used monocyte-derived DCs, since they can
be generated at sufficient numbers to allow functional experiments. When we infected
purified B cells with EBV and co-cultured them with resting purified peripheral blood NK
cells at ratios of 5:1 (NK to B cells) we could not observe any restriction of B cell
transformation.

Similarly, addition of iDCs or cyt DCs induced only limited NK cell-

mediated inhibition of EBV-transformed B cell outgrowth (6 or 13%, respectively) (Figure
9A, B and C). However, in cultures with NK cells and poly(I:C) DCs or DC1s, we
observed a 49 or 55 % (both p < 0.01) reduction of the number of transformed B cells,
respectively (Figure 9C). The DC preparations used in this study had no significant direct
effect on B cell transformation by EBV (data not shown). This demonstrated that DCactivated NK cells can inhibit B cell transformation by EBV.
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Figure 9: NK cells from blood activated by poly(I:C)-matured DCs limit EBV-mediated B cell
transformation. (A) B cells were infected with EBV and cultured for 12 d alone, with DCs or NK cells and
with DCs plus NK cells. The indicated percentage of B cell transformation was evaluated by determining the
percentage of transformed CD19+CD23+B cells within gated CD19+CD21+ B cells. (B and C) Total numbers
of transformed B cells were determined from live cell numbers and the percentage of transformed
CD19+CD23+B cells in the different cultures. Total transformed B cell numbers for one representative
experiment (B), and differences in total transformed B cell numbers for all experiments as regression (C),
with and without NK cells were plotted for the indicated DC maturation conditions. Data represent results
from eight independent experiments (mean ± s.e.m.).

3.1.4

Low numbers of tonsillar NK cells restrict EBV induced B cell
transformation.

Tonsils are the primary infection sites for EBV and harbor enriched populations of
CD56brightCD16- NK cells, which can be efficiently activated by DCs. Therefore, we
investigated whether tonsillar NK cells can restrict EBV-induced B cell transformation.
For this purpose, we depleted tonsillar mononuclear cells of CD3+ T cells by cell sorting

59

and compared the numbers of transformed B cells after EBV infection to cultures that
were depleted of both CD3+ T and CD56+ NK cells (Figure 10A and B). Without addition
of DCs and with the addition of allogeneic iDCs or cyt DCs, we did not observe any
significant difference in the number of transformed B cells after 12 days (Figure 10A and
B). However, we observed a 35 % or 42 % (p < 0.03 and p<0.01) reduction of the
number of transformed B cells after addition of allogeneic poly(I:C) DCs or DC1s,
respectively (Figure 10B). These data suggest that tonsillar NK cells are able to restrict
B cell transformation by EBV after stimulation by poly(I:C) DCs and DC1s. NK cells are
present in tonsils at lower frequencies than in peripheral blood (0.3 % compared to 10
%), corresponding to only 3000 NK cells in a tonsillar B cell transformation assay with 6
x 105 B cells (NK to B cell ratio of 1:200). However, the ratio between CD56dimCD16+ and
CD56brightCD16- NK cells is almost reversed between these organs with 75% of all NK
cells being CD56brightCD16- in tonsils and only 5% being CD56brightCD16- in peripheral
blood (Ferlazzo and Münz, 2004). To compare directly the abilities of NK cells from
blood and tonsils to restrict B cell transformation, we tested different ratios of blood NK
cells to B cells. In addition to an intermediate ratio (NK:B = 1:1), we mimicked NK cell to
B cell ratios found in tonsils (NK:B = 1:200; 60% B and 0.3% NK cells). We also added
sufficient peripheral blood NK cells to mimic the CD56brightCD16- NK cell to B cell ratio
found in tonsil (NK:B = 1:13.3; CD56brightCD16- NK cells are 15fold enriched in bulk
tonsillar NK cells compared to blood NK cells: 75% in tonsil and 5% in blood). Already at
a ratio of 1:1 we could only detect a limited 6 % reduction of B cell transformation
compared to controls (Figure 10C and D). These findings indicate that tonsillar NK cells
are 1000-fold more efficient in controlling B cell transformation than peripheral blood NK
cells.
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Figure 10: NK cells from tonsil activated by poly(I:C)-matured DCs limit EBV-mediated B cell
transformation at lower numbers than blood NK cells. (A and B) Mononuclear cells from tonsils were
depleted of CD3+ T cells or CD3+ T and CD56+ NK cells. Total numbers of transformed B cells were
determined from live cell numbers and the percentage of transformed CD19+CD23+ B cells in the different
cultures. Total transformed B cell numbers for one representative experiment (A), and differences in total
transformed B cell numbers for all experiments as regression (B), with and without NK cells were plotted for
the indicated DC maturation conditions. (C and D). B cells were infected with EBV and cultured for 12 d
alone, with DC1s or NK cells and DCs at the indicated NK cell to B cell ratios. Total NK cells were compared
to sorted CD56brightCD16- and CD56dimCD16+ NK cells in their ability to limit EBV-mediated B cell
transformation. To reflect the frequencies of NK subsets in peripheral blood for the different ratios, total
transformed B cell numbers for one representative experiment (C) and regression for all experiments (D),
mediated by total NK cells was compared to the effect seen with 90 % of CD56dimCD16+ NK cells or 10% of
CD56brightCD16- NK cells (*: p < 0.01).

3.1.5

CD56brightCD16- NK cells restrict EBV induced B cell transformation most
efficiently.

To study which subset of NK cells limits B cell transformation, we sorted NK cell subsets
from blood and activated them with DC1s. While sorted CD56dimCD16+ NK cells did not
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mediate restriction of B cell transformation (NK:B = 4.5:1), low numbers of
CD56brightCD16- NK cells (NK:B = 1:2) were found to inhibit B cell transformation (34 %)
similar to 10-fold higher numbers of bulk NK cells (Figure 10 C and D). Next, we sorted
NK cell subsets from tonsils and observed that again CD56bright CD16- NK cells but not
CD56dimCD16+ NK cells were efficiently limiting B cell transformation after activation by
DC1 (Figure 11A and B). At 10-fold lower numbers, tonsillar CD56bright CD16- cells
inhibited B cell transformation more (48.3 % vs. 34 %) than their counterparts in blood.
Since CD56brightCD16- NK cells are 15-fold enriched in tonsils compared to blood, NK cell
mediated restriction is achieved with at least 150-fold lower bulk NK cell numbers in this
organ. Further increasing the number of tonsillar NK cells 5-fold (NK:B = 1:40) led to
restriction of B cell transformation by 69.7 % (Figure 11B). Moreover, high numbers of
splenic CD56brightCD16- NK cells (NK:B = 5:1), a mixture of blood and secondary
lymphoid organ NK cells, when activated with matured autologous myeloid CD11chigh
DCs isolated from spleen, restricted B cell transformation by 67 % (Figure 11C and D).
Since we observed that at lower ratios of blood NK cells to B cells, even purified
CD56brightCD16- peripheral blood NK cells were unable to limit B cell transformation after
activation by poly(I:C) DCs and DC1s, whereas tonsillar NK cells were still able to restrict
EBV-induced B cell transformation, we concluded that tonsillar CD56bright CD16- NK cells
are functionally different from their counterparts in peripheral blood, and inhibit EBV
induced B cell transformation more efficiently.
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Figure 11: CD56brightCD16- cells from tonsil and spleen limit EBV-mediated B cell transformation after
activation by DCs. (A and B) Tonsillar B cells were infected with EBV and cultured for 12 d alone or with
autologous purified NK cell subsets at 2 ratios (NK: 5,000, and 5-fold NK: 25,000) in the absence or
presence of allogeneic iDCs or DC1s (*: p < 0.01). Total transformed B cell numbers for one representative
experiment (A), and regression for all experiments are shown (B). (C and D) Splenic B cells were infected
with EBV and cultured for 12 d alone or with splenic NK cell subsets in the absence or presence of
autologous splenic DCs matured with poly(I:C), TNF-, IL-1, IFN- and IFN- (*: p < 0.01). Total
transformed B cell numbers for one representative experiment (C), and regression for all experiments are
shown (D). Data in (A) to (D) represents results from three independent experiments (mean ± s.e.m.).

3.1.6

Tonsillar and lymph node NK cells produce higher levels of the anti-viral
cytokine IFN- than peripheral blood NK cells.

Human NK cells from secondary lymphoid organs such as tonsils produce IFN- rapidly
upon activation and this antiviral cytokine contributes directly to control early infection in
murine models of herpes virus infection (Orange et al., 1995). When we compared the
production of IFN- upon NK cell/DC co-culture, we observed that NK cells from tonsil
and lymph node produced significantly more IFN- than their equivalents from blood or
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spleen (Figure 12A). Comparing CD56bright CD16- NK cells, tonsillar and lymph node cells
produced 5-fold more IFN- than peripheral blood cells, which amounted to a 50-fold
difference when bulk NK cell cultures were analyzed due to the enrichment of
CD56brightCD16- NK cells in these organs. It had recently been reported that IL-18
exposed blood NK cells develop into a CD56brightCD83+CCR7+ NK cell subset with
superior IFN- production (Mailliard et al., 2005). In order to test if an enrichment of this
NK cell subset could account for the superior ability of tonsillar NK cells to produce IFN, we analyzed CD83 and CCR7 expression on tonsillar NK cells (Figure 13). Confirming
our previously published data (Ferlazzo et al., 2004b), we found no CCR7 expression on
tonsillar NK cells, and only a minor population expressed CD83. Therefore, an
enrichment of CD83+CCR7+ NK cells with superior IFN- production does not explain
why NK cells from secondary lymphoid organs produce more IFN- than their peripheral
blood counterparts.
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Figure 12: IFN- secreted by NK cells restricts EBV-mediated B cell transformation. (A) Sorted NK cell
subsets from blood, spleen, tonsil and lymph node were cultured alone or with DC1s, and IFN- levels were
quantified by ELISA after 20h. (B) IFN- secreted by tonsillar NK cells after activation by differently matured
DCs during the regression assay was detected in supernatants by ELISA. (C) IFN- secreted by peripheral
blood NK cells and NK cell subsets during regression assays was detected in supernatants by IFN- ELISA
(Tonsil–T: tonsillar cultures depleted of T cells, Tonsil–T-NK: tonsillar cultures depleted of T and NK cells).
(D) IFN- secreted by tonsillar NK cell subsets during regression assays was detected in supernatants by
IFN- ELISA. Results from at least three independent experiments were summarized (mean ± s.d.) (*: p <
0.03).
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Figure 13: Tonsillar NK cells do not express CCR7 and only a low number expresses CD83.
Mononuclear cells from tonsil were stained with CD3 and CD56 to identify CD3-CD56+ NK cells. In addition
cells were stained with antibodies against CD16 and CD83 or CCR7. (A) shows a representative
experiment, and (B) summarizes data from four independent experiments (mean ± s.d.).

3.1.7

IFN- levels correlate with NK cell induced restriction of B cell
transformation by EBV.

Higher IFN- secretion by tonsillar NK cells was also apparent when we then quantified
the levels of IFN- in the culture supernatants of the B cell transformation assay after 12
days. We detected high levels in co-cultures of NK cells from blood with poly(I:C) DCs
(960 pg/ml; data not shown) or DC1s (1560 pg/ml; Figure 12C), but only with the highest
numbers of NK cells (NK:B = 5:1). However, IFN- levels were even higher in B cell
transformation cultures with bulk tonsillar NK cells and poly(I:C) DCs (1140 pg/ml) or
DC1s (2500 pg/ml), and this IFN- secretion was NK cell dependent (Figure 12B).
Furthermore, we detected similar levels of IFN- also in cultures with sorted
CD56brightCD16- NK cells from blood, tonsil and spleen (Figure 12C, D and data now
shown), reaching up to 4000pg/ml IFN- concentrations with purified tonsillar
CD56brightCD16- NK cells. Therefore, only DC/NK cell co-cultures with poly(I:C) matured
DCs and either high peripheral blood or low tonsillar NK cell numbers produce IFN-
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concentrations above 1000 pg/ml, and only these high IFN- levels correlate with control
of EBV transformed B cells.

3.1.8

Restriction of EBV induced B cell transformation by NK cells relies on
IFN-.

In order to estimate the contribution of NK cell-produced IFN- on control of EBV-infected
B cells, we added recombinant IFN- to purified and EBV infected B cells from blood,
spleen and tonsil. We detected fewer transformed B cells in cultures with high levels of
IFN- (from 1000 to 10000 pg/ml) compared to controls with low levels (from 10 pg/ml to
200 pg/ml) of IFN- or without IFN- (Figure 14A). Indeed, 42% restriction of B cell
transformation (p < 0.02) was observed in tonsillar B cell cultures with 5000 pg/ml IFN-,
an IFN- concentration that was produced by tonsillar NK cells upon culture with
poly(I:C) DCs and DC1s, and similar to measured IFN- levels in tonsil cell cultures
(Figures 12A and D). However, IFN- mediated restriction of B cell transformation by
EBV only limits, but does not eradicate EBV infection, since even with IFN-
concentrations exceeding 10,000 pg/ml, we never observed more than 80% inhibition of
B cell transformation by EBV (data not shown). Finally, DC activated NK cell were still
able to mediate restriction when separated by transwell from EBV infected B cells, and
we could block inhibition of B cell transformation by over 60 % using blocking antibodies
against IFN- (Figure 14B). Therefore, IFN- contributes to NK cell-mediated restriction
of EBV-induced B cell transformation.
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Figure 14: IFN- secreted by NK cells is sufficient and necessary to restrict EBV-mediated B cell
transformation. (A) Peripheral blood B cells were infected with EBV and increasing concentrations of IFN-
were added. Regression of B cell transformation was analyzed after 12 d by comparing numbers of
transformed B cells with and without IFN-. (B) Blocking antibodies against IFN- were added to regression
assay with B cells, NK cells, and DC1s from peripheral blood. In addition, NK cells were separated from B
cells and DCs by transwell membranes. Results from at least three independent experiments were
summarized (mean ± s.d.) (*: p < 0.03).

3.1.9

Myeloid DCs sense EBV directly and elicit IFN- secretion by NK cells to
levels protective against EBV induced B cell transformation.

In order to extend our findings from monocyte-derived DCs to human blood DCs and
from poly(I:C) to maturation by EBV, we exposed sorted human CD11c+ myeloid DCs to
EBV particles directly (DC:EBV MOI = 1:1). We observed 189 ± 20 pg/ml IL-12 secretion
and upregulation of the maturation marker CD83 upon co-culture of myeloid DCs with
EBV (Figure 15A and B). Both infectious and heat-inactivated EBV elicited this DC
maturation (Figure 15A). DC maturation by EBV was not due to endotoxin contamination
of the EBV virus preparations, since we detected less than in 0.1 ng endotoxin in 1x105
EBV RIU, a concentration insufficient for human DC maturation (Figure 15A).
Furthermore polymyxin B, which inhibits TLR4 stimulation by LPS (Duff and Atkins,
1982), had no effect on EBV mediated DC maturation, but significantly inhibited DC
maturation by LPS (Figure 15A). While EBV induced IL-12 levels were lower than IL-12
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concentrations in response to poly(I:C) and to high levels of LPS (1286 ± 188 pg/ml and
763 ± 87 pg/ml, respectively; Figure 15A), EBV matured DCs stimulated purified
autologous NK cells to secrete IFN- in excess of 4000 pg/ml via IL-12 (Figure 15C).
These IFN- concentrations are high enough to inhibit B cell transformation by EBV in

vitro (Figure 14A). These data suggest that human myeloid DCs can be matured by EBV
and then activate NK cells to produce protective amounts of IFN-.

Figure 15: Myeloid DCs can sense EBV and activate subsequently NK cells via IL-12. (A) CD11c+
myeloid DCs (1x105) were purified to 99.8 % purity by flow cytometric sorting and exposed to poly(I:C) (25
μg/ml), EBV (non-treated or heat-inactivated) (5x105 RIU/ml) and LPS in the absence and presence of
polymyxin B (25 μg/ml), an inhibitor of LPS-mediated TLR4 activation. IL-12p70 was detected by ELISA 24 h
later. (B) Purified DCs were exposed to poly(I:C) (25 μg/ml) or EBV (5x105 RIU/m) and upregulation of the
DC maturation marker CD83 was detected by flow cytometry 24 h later. (C) Flow-sorted CD11c+ DCs and
NK cells were cultured together or separate in the presence of poly(I:C) (25 μg/ml), or EBV (5x105 RIU/ml).
IFN- was detected by ELISA 24 h later. Additionally, IL-12 was blocked in selected experiments using
blocking antibody (n.t.: not tested). Data represents results from six (A, except heat-inactivated EBV) or
three independent experiments performed in duplicates.
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3.1.10 IFN- regulates B cell transforming EBV latency.
In order to investigate how IFN- restricts B cell transformation, we infected B cells with
EBV and compared total cell numbers, proliferation and expression of EBV-encoded
genes between untreated and IFN--treated cells. We started observing significant
differences in cell numbers from day 4 (Figure 16A). This coincided with beginning EBVinfected B cell proliferation, which was delayed when cells were treated with IFN-
(Figure 16B). Comparing expression of different EBV-encoded genes showed that
EBER1, EBNA2, and EBNA1 were similarly up-regulated in untreated and IFN--treated
EBV infected B cells. In contrast, we observed a delayed up-regulation of LMP1 in IFN-treated cultures (Figure 16C and data not shown). Quantitative RT-PCR demonstrated
that expression of LMP1 was reduced by 28% and 49% at days 3 and 5 post infection,
while at later stages similar LMP1 levels were observed with and without IFN- addition,
when normalized to GAPDH (Figure 16D). Notably, recombinant IFN- did not mediate
restriction of B cell transformation when added later than 96h after EBV infection (Figure
16E), and also did not inhibit growth of established EBV-transformed B cell lines (data
not shown). We did not observe any effect of IFN- on B cell viability as measured by
counting live cells up to day 6 post-infection, and levels of the EBV receptor CD21 were
not affected by IFN- treatment (data not shown). Therefore, we suggest that DC
activated NK cells limit B cell transformation by EBV via regulation of EBV latent
infection, at least in part via delaying LMP1 expression via IFN-.
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Figure 16: IFN- impairs transformation of B cells by EBV. (A) Cell numbers were compared at different
time points between control and IFN--treated B cells with and without EBV infection. (B) CFSE-labeled B
cells were infected with EBV and proliferation was compared between controls and IFN--treated samples at
the indicated time points. (C) Expression of EBV-encoded genes was quantified by RT-PCR at different time
points and compared between controls and IFN--treated cells. M: 100 bp ladder (D) Expression of the
oncogene LMP1 was quantified by RealTime-PCR and normalized to GAPDH expression. Results represent
data from at least three independent experiments. (E) Peripheral blood B cells were infected with EBV and
10,000 pg/ml IFN- was added at the indicated time points. Regression of B cell transformation was
analyzed after 12 d by comparing numbers of transformed B cells with and without IFN-.
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3.2
3.2.1

Studying immune responses against EBV in vivo
Immune reconstitution of NOD-scid  c-/- mice injected with human CD34+
hematopoietic stem cells

In order to generate mice susceptible to EBV infection and hence potentially capable of
generating EBV specific human immune responses in vivo, we compared previously
described mouse models for human immune system reconstitution (NOD-scid c-/- and
Rag2-/-c-/- mice) (Gimeno et al., 2004; Ishikawa et al., 2005; Shultz et al., 2005; Traggiai
et al., 2004). For this purpose, we engrafted irradiated newborn Rag2-/-c-/- and NOD-scid
c-/- mice with human fetal liver-derived CD34+ HSCs. We observed higher levels of
primarily human T and NK cell reconstitution in NOD-scid c-/- mice (Figure 17A) and
therefore pursued this model, to which we will refer as hu-NSG mice in the remainder of
the text. In hu-NSG mice, we consistently achieved reconstitution of 20 to 50 mice from
the same graft with similar reconstitution efficiency of B cell and T cell frequencies in
peripheral blood after three months (Figure 17B). In reconstituted mice, frequencies of
human CD45+ were routinely above 60 % of total splenocytes after four months of
reconstitution (Figure 17C) with the majority (80-90%) being B and T cells (ratio 2:1 for
B:T cells, and 3:2 for CD4+ to CD8+ T cells). Additionally, CD123+ plasmacytoid (1-2%)
and CD11c+ myeloid dendritic cells (1-2%), monocytes (1-2%) and NK cells (2-5%) were
also detected (Figure 17C and see section 3.3.1). Furthermore, human CD45+ cells and
all major subsets of human immune cells were detected in thymus, mesenteric lymph
node, bone marrow, liver, and lung of hu-NSG mice (data not shown).
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Figure 17: Multilineage reconstitution of NSG mice with human immune cells. Newborn NSG mice
+
were reconstituted with CD34 stem cells and were analyzed 12 weeks later for the presence of human
cells. (A) Total splenocytes were analyzed fro the presence of human leukocytes, B cells , T cells and DC
subsets. One representative example is displayed. (B) Summary of reconstitution in the peripheral blood of
several litters of NSG mice that were reconstituted with cells from the same donor.

Compared to the structured architecture in human secondary lymphoid organs such as
lymph nodes or tonsils, immune cells in the spleen of hu-NSG mice showed a primitive
organization into white and red pulp (Figure 18). In summary, in line with previous
findings, we successfully achieved human multi-lineage reconstitution in NOD- scid c-/-
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mice after neonatal HSC transfer, thus generating a small animal model with the
potential to generate human immune responses in vivo.

Figure 18: Primitive structural organization of the secondary lymphoid organs in hu-NSG mice.
Immunohistological characterization of the spleen of humanized mice four month after reconstitution in
comparison to a human tonsil (10x magnification). The indicated stainings characterize B (CD21, CD20), T
(CD3), and myeloid cells (CD68).

3.2.2

EBV infection of humanized mice

In order to test the ability of the reconstituted human immune system to generate
pathogen specific immune control, we infected hu-NSG mice with EBV, a human
tumorvirus that is efficiently immune controlled in the majority of infected individuals. We
chose an infectious dose that would roughly reflect the number of virus particles in 100 μl
of saliva from a symptomatic EBV converter (Fafi-Kremer et al., 2005). After injection of
hu-NSG mice with 105 RIU of purified viral particles intraperitoneally, EBV infected cells
were readily detectable in the spleen, 4 weeks post-infection by in situ hybridization for
EBERs, while we did not detect any EBER+ cells in mock-infected animals (Figure 19A).
At later time points, we also detected EBER+ cells in the lymph nodes and livers of most
infected animals (Figure 19A). In the spleen of infected animals, EBER+ cells were
consistently surrounded by CD3+ T cells (Figure 19B). Furthermore, when EBER+ cells
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were detected in non-lymphoid organs such as liver and kidney, these infected cells
were again in close proximity to CD3+ T cells, suggesting that T cells can home to similar
peripheral sites as EBV infected cells in hu-NSG mice (Figure 19B). In order to
characterize the latency type of EBV infected cells, we stained spleen sections for the
two EBV-encoded proteins EBNA2 and LMP1. We did not detect any LMP1 single
positive cells, but we found similar frequencies of EBNA2+ compared to EBER+ cells,
some of which also expressed LMP1, indicating a latency III of EBV infection (Figure
19C). These results suggest that hu-NSG mice establish latent EBV infection, which
constitutes the basis of B cell transformation by EBV.
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Figure 19: EBV infected cells are detected in hu-NSG mice in multiple organs and express EBNA2
and LMP1. (A) EBV infected cells could be detected in the indicated organs by EBER hybridization (10x
magnification). (B) EBER+ cells were surrounded by T cells (CD3+) both in spleen and after migration to the
kidney. (Right panels 40x magnification, others are 10x magnification) (C) EBNA2+ cells co-expressed LMP1
in the spleen (Left panel is 40x magnification, right panel is a magnification of the left panel).

3.2.3

Development of HLA restricted EBV specific human T cell responses in
infected hu-NSG mice

Since we rarely observed tumors after six weeks of infection in hu-NSG mice, we
determined whether they developed EBV specific T cell responses, which are believed to
protect healthy human carriers from EBV associated malignancies (Hislop et al., 2007;
Khanna and Burrows, 2000). For this purpose, we first analyzed the splenic lymphocyte
composition of the infected animals by flow cytometry. We found dramatic expansions of
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CD3+ T cells among the human CD45+ leukocytes after EBV infection, which was
accompanied by a corresponding increase in the percentage of CD8+ cells among the
human T cells (Figure 20A). On average, we observed a statistically significant two-fold
expansion of splenic CD8+ CD3+ T cells in 10 independent experiments with a total of 40
mice (Figure 20B). In addition, both in the CD8+ and the CD4+ compartments, there was
a marked upregulation of HLA-DR and CD45RO surface expression, indicating an
activated memory phenotype of the expanded T cells, which is also seen in humans
during symptomatic primary EBV infection (Hislop et al., 2007; Khanna and Burrows,
2000).

Figure 20: Expansion of human CD3+ T cells after EBV infection (A) Splenocytes from control or EBV
infected animals were harvested six weeks after infection. Frequencies of lymphocyte subsets were
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determined by flow cytometry. Activation and memory phenotype of both the CD4+ and CD8+ T cells was
monitored by measuring the upregulation of the HLA-DR and CD45RO surface markers, respectively.
Representative data of 10 experiments are shown. (B) Summary of CD3+CD8+ T cell expansion for 40 mice
in 10 different experiments.

Figure 21: Dose dependent induction of HLA restricted T cell responses against autologous EBV
transformed B cells in infected hu-NSG mice (A) Reconstituted NSG mice were infected with 105 or 106
Raji infectious units of EBV. Six weeks after infection, human B cell depleted splenocytes were incubated
with autologous EBV transformed B cells (LCL) to measure EBV specific IFN- secretion using ELISPOT
assays. IFN- specific spots per 10 5 cells are shown for a representative experiment with 3 mice in each
group. One representative of 6 experiments is shown. (B) Humanized NSG mice were infected with 106 Raji
units of EBV. Six weeks after infection, splenocytes were harvested from control and infected animals and T
cell reactivity was evaluated by IFN- ELISPOT assays under similar conditions as described in (A).
Staphylococcal enterotoxin B (SEB) superantigen and allogenic LCLs were used as positive and negative
controls, respectively. Human HLA restriction was determined using inhibitory antibodies against HLA I and
II as indicated. One representative of 2 experiments is shown.

We next examined whether T cells from infected animals would respond to autologous
EBV transformed B cells presenting viral antigens by human MHC molecules. For this
purpose, we first established lymphoblastoid cell lines (LCL) by in vitro infection of B
cells derived from a littermate mouse reconstituted with cells from the same HSC donor
used for reconstitution of the EBV infected animals. B cell depleted splenocytes isolated
from control and infected animals were incubated with these autologous LCL and IFN-
secretion was monitored by ELISPOT assays. A significant amount of IFN- production
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was detected in response to autologous LCL whereas responses to allogeneic LCL were
comparable to background IFN- production (Figure 21A and B).

In addition, EBV

specific T cells responses were much more vigorous from animals infected with higher
doses of EBV (Figure 21A) suggesting that T cells can be primed in a dose dependent
manner.

LCL recognition could be blocked by pretreatment with antibodies against

either HLA-A/B/C, HLA-DR/DP/DQ, or combinations thereof (Figure 21B and data not
shown), clearly indicating that HLA restricted, EBV specific CD8+ and CD4+ human T
cells were primed in hu-NSG mice upon infection with EBV.

3.2.4

Isolation of EBV-specific T cell clones

In order to analyze the peptide epitope specificity and effector functions of the in vivo
primed EBV specific T cell responses, we isolated splenocytes from infected hu-NSG
mice reconstituted with HLA-A2+ HSCs 10 weeks post EBV infection. After labeling with
CFSE, these splenocytes were stimulated with either autologous LCLs or a pool of 33
peptides derived from lytic and latent EBV antigens (Figure 21A). To enrich for LCLspecific or peptide-specific cells, CFSElow T cells were sorted after 6 days by flow
cytometry, cloned by limiting dilution, and finally retested with either autologous LCLs or
the pool of 33 EBV derived peptides in IFN- ELISPOT assays, respectively. We were
able to identify three CD8+ T cell clones that recognized the library of 33 peptides, and
subsequently tested them against a matrix of smaller peptide libraries allowing us to
identify the individual peptides recognized by the clones (Figure 22A). All three clones
recognized a peptide derived from LMP1, LMP1167-176 (Figure 22A), which has been
described to be recognized by CD8+ T cells in EBV+ infected HLA-A2+ individuals
(Khanna and Burrows, 2000). Titration of the cognate peptide on one of the clones
(CD8-LMP1) showed recognition down to 10 nM indicating high affinity towards the
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peptide (Figure 22B). We furthermore identified CD4+ and CD8+ T cell clones that
recognized the autologous LCL in IFN- ELISPOT assays. Subsequently, we compared
the cytotoxicity of three of these LCL specific clones (#1-3) and one of the LMP1 specific
CD8+ T cell clones (CD8-LMP1) against autologous LCL, and found that one of the two
CD4+ T cell clones, the LCL specific CD8+ T cell clone, and the LMP1 specific CD8+ T
cell clone were able to lyse autologous LCL at similar effector to target ratios (Figure
22C). In addition, these T cells also degranulated and secreted IFN- in response to LCL
recognition (Figure 22D). These data indicate that multifunctional cytotoxic EBV specific
T cells are primed in hu-NSG that can kill EBV transformed B cells.
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Figure 22: Isolation of EBV specific T cell clones from infected hu-NSG mice. (A) T cell clones were
established by limiting dilution cloning from sorted CFSElow T cells, that had proliferated in response to EBV
transformed B cells (LCL) or EBV derived peptides, The library of 33 EBV peptides that was used for the
initial T cell proliferation was divided into the indicated matrix of peptide pools and used to assess the fine
specificity of obtained T cell clones. Reactivity of one out of three CD8+ T cell clones specific for the HLA-A2restricted peptide LMP1167-176 in IFN- ELISPOT is shown. (B) Epitope affinity was determined by cognate
peptide titration on LMP1167-176 specific CD8+ T cells in IFN- ELISPOT assays. One representative of 2
experiments is shown. (C) The cytotoxicity of LMP1 167-176 specific (CD8-LMP1) and LCL specific (#1-3) CD4+
and CD8+ T cell clones against autologous EBV transformed B cells (LCL) was assessed by flow cytometric
To-Pro-3-iodide exclusion assays at the indicated effector to target ratios (E:T). One representative of 3
experiments is shown. (D) Degranulation and IFN- production was evaluated after co-culture with
autologous LCLs by flow cytometric surface staining for CD107a and intracellular IFN- staining. One
representative of 3 experiments is shown.

81

3.2.5

Disseminated EBV associated malignancies in T cell depleted hu-NSG
mice

To study the role of these in vivo primed EBV specific T cells in controlling EBV infection
and EBV associated malignancies in hu-NSG mice, we depleted T cells prior to EBV
infection using antibodies against the CD4 and CD8 cell surface antigens (data not
shown). Four to five weeks post infection, mice were analyzed for the development of
tumors as well as for EBV viral loads. While we observed small splenic tumors in only 3
of the 17 EBV infected animals with or without isotype control antibody injection, all 11 T
cell depleted animals developed disseminated EBV positive tumors in spleen,
mesenteric lymph node, kidney, or liver (Figure 23A). Histological analysis showed
expansion of white pulp regions in the enlarged spleens of T cell depleted and infected
mice, which contained almost exclusively EBER+ CD20+ B cells (Figure 23B and data not
shown). The majority of these cells expressed EBNA2, once again indicating a latency III
expression pattern (Figure 23B). In addition, we observed a similar phenotype of the
EBER+ cells located in the LN, liver, and kidney. Furthermore, viral DNA loads increased
significantly in T cell depleted mice compared to infected mice (3.2x106 vs. 1.9x105, p =
0.003) indicating uncontrolled EBV infection after T cell depletion. In summary, these
results indicate that hu-NSG mice are able to prime human EBV specific T cell
responses that protect mice against uncontrolled EBV infection and EBV associated
malignancies.
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Figure 23: Development of EBV associated tumors after T cell depletion in EBV infected hu-NSG
mice. (A) Disseminated tumors in EBV infected animals following T cell depletion. T cell depletion in EBV
infected hu-NSG mice resulted in splenomegaly and EBV positive tumors either in kidney, mesenteric lymph
node, or liver (arrows). T cell depleted and EBV infected hu-NSG mice (EBV/CD4+CD8, n=11) were
compared to EBV infected hu-NSG mice (EBV, n=13), EBV infected hu-NSG mice treated with isotype
control antibodies (EBV/iso, n=4) and uninfected hu-NSG mice (control, n=11). Representative pictures are
shown. (B) Immunohistological characterization of representative spleen sections of T cell depleted and EBV
infected, EBV infected and mock treated or uninfected hu-NSG mice. Splenic architecture was assessed by
hematoxylin and eosin staining (HE), EBV infected cells were identified by either EBER in situ hybridization
(EBER) or staining with EBNA2 specific antibodies (EBNA2), and T and B cell content was characterized by
CD3 and CD20 specific antibody staining, respectively (HE 5x magnification, CD3/EBER and CD20/EBNA2
10x magnification).
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Figure 24: Elevated viral loads in T cell depleted and EBV infected hu-NSG mice (A) Splenic EBV
loads were determined by quantitative real-time PCR four weeks after EBV infection. Viral titers were
calculated from three independent experiments with a total of 39 animals (see above). No EBV titers were
detected in uninfected hu-NSG mice (control). (B) Total splenic EBV loads were determined by multiplying
splenic viral loads determined as in (C) with total splenocyte numbers determined by counting. Results are
shown for seven control mice, nine EBV infected mice, four EBV infected and isotype control antibody
treated mice, and eight T cell depleted and EBV infected mice. (C) EBV episome copy numbers in 106
splenocytes were determined in EBV infected hu-NSG mice after CD4+ (CD4) and CD8+ T cell (CD8)
single depletions, as well as double depletion (CD4+CD8). Composite data of two independent
experiments are shown. (D) Total viral loads per spleen were calculated from the viral copy numbers per 106
cells multiplied by the total counted splenocyte numbers. Statistical significance for all data was assessed
with the Mann-Whitney U test, *: p < 0.03.
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3.2.6

EBV-specific CD4+ and CD8+ T cells contribute both to the immune control
of EBV in vivo

In humans, in vitro studies have demonstrated the presence of both CD4+ and CD8+
EBV-specific T cells in healthy individuals, however the contributions of each of them to
successful immune control of EBV in vivo has not been analyzed. In order to compare
the contributions of CD4+ and CD8+ T cells to the T cell-mediated immune control of EBV
infection, we then depleted T cell subsets separately. Viral titers increased significantly
both after the depletion of CD4+ and CD8+ T cells compare to EBV-infected animals
(EBV: 6.4x105, CD4: 1.9x106, CD8: 3.2x10e6, CD4+CD8: 1.3x107 per 106
splenocytes, p < 0.03, and EBV: 1.5x107, CD4: 7.2x107, CD8: 1.2x10e8, CD4+CD8:
8.6x108 per spleen, p < 0.03) (Figure 24) increased significantly in all groups. However,
neither the separate depletion of CD4+ and CD8+ T cells increased the viral titers as
much as the depletion of both CD4+ and CD8+ T cells in these experiments. Notably, we
observed in all (n=4) pan-T cell-depleted and in 3 of 4 CD8-depleted animals the
occurrence of tumors in the spleens and mesenteric lymph nodes, but only in 1 of 4 CD4
depleted animals. This indicates that both CD4+ and CD8+ T cells contribute to the
immune control of EBV in vivo, but additional experiments will be necessary to analyze
how CD4+ T cells participate in the immune response.

3.2.7

Improved detection of EBV-peptide specific CD8 T cell responses in HLAA2 transgenic hu-NSG mice

Since we were able to identify EBV derived peptide epitopes for our isolated T cell
clones only occasionally from EBV infected hu-NSG mice, we aimed to bias EBV specific
T cell recognition to peptides epitopes that dominate EBV specific immune control in
humans by introducing a HLA-A2 transgene into NSG mice (NSG-A2). We reconstituted
a group of regular NSG mice and NSG mice transgenic for HLA-A2 with CD34+ cells
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from the same HLA-A2+ donor (hu-NSG and hu-NSG-A2, respectively). Human immune
cells and in particular human CD4+ and CD8+ T cells developed in both groups of mice
with similar frequencies and distributions (Figure 25).

Figure 25: Similar reconstitution of hu-NSG and hu-NSG-A2 mice. Littermate wildtype and HLA-A2
+
transgenic newborn NSG mice (n=5 each) were reconstituted with HLA-A2 stem cells and were analyzed
12 weeks later for the presence of human cells. Expression of the HLA-A2 transgene on mouse cells was
verified by flow cytometry.

We infected hu-NSG and hu-NSG-A2 mice with EBV and 5 weeks p.i. we stimulated
splenocytes from these mice with two pools of EBV-derived HLA-A2-restricted peptides,
one containing 8 lytic epitopes and one containing 12 latent epitopes. We detected in all
(n = 5) EBV-infected hu-NSG-A2 mice IFN- secretion by ELISPOT after stimulation with
the lytic pool, but only in 4 of 5 mice after stimulation with the latent pool (Figure 26A).
Notably, these latent responses were significant lower than the lytic responses (11 vs.
70 SFU/2x105 cells, p = 0.04). Moreover, no IFN- secreting cells were detected in any of
the control mice or in EBV-infected hu-NSG mice reconstituted with HLA-A2+ matching
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(n=2) or non-matching (n=8) CD34+ cells. Interestingly, after stimulation with autologous
LCLs, splenocytes from both EBV-infected hu-NSG and hu-NSG-A2 responded similarly
(107 vs. 124 SFU/2x105 cells). In order to detect EBV-specific CD8+ T cells directly,
splenocytes were stained with a control tetramers (HIV GAGSLY), and two wellcharacterized EBV tetramers derived from a lytic epitope (BRLF1YVL) and a latent epitope
(LMP2CLG), respectively. While we did not detect any tetramer-positive cells in control huNSG and hu-NSG-A2 mice as well as EBV-infected hu-NSG mice, 3 of 5 EBV-infected
hu-NSG-A2 mice developed up to 2.7% BRLF1YVL tetramer positive CD8+ T cells (Figure
26B and C). These tetramer-positive cells had an activated phenotype being exclusively
CD45RO+HLA-DR+. But, also in these mice we did not observe any cells positive for the
LMPCLG tetramer, possibly because their frequency was too low. These experiments
suggest that HLA transgenic hu-NSG mice bias primary T cell responses of reconstituted
human immune system components towards recognition of EBV derived peptide
epitopes that are dominant during EBV infection in humans
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Figure 26: Enhanced priming of CD8+ T cell responses against dominant EBV peptides in HLA-A2
transgenic hu-NSG mice. (A) HLA-A2 transgenic and non-transgenic NSG mice were reconstituted with
HLA-A2+ CD34+ HSCs from the same donor. 4 weeks after EBV infection or mock treatment, splenocytes
were restimulated for IFN- ELISPOT assays with medium alone, SEB as a positive control, the autologous
EBV transformed B cell line (LCL), 8 lytic EBV antigen derived dominant CD8+ T cell epitopes and 12 latent
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EBV antigen derived CD8+ T cell epitopes, which had been defined as dominant CD8+ T cell epitopes in
human EBV carriers. The data summarize two independent experiments. (B and C) In parallel, tetramer
staining on splenocytes of EBV infected or control mice was performed ex vivo. Tetramers of HLA-A*0201
with the HIV gag77-85 (GAGSLY), EBV LMP2 aa426-434 (LMP2CLG) or EBV BRLF1 aa109-117 (BRLF1YVL)
peptides were used in co-staining with anti-CD8 and analyzed by flow cytometry. (B) shows a representative
experiment and (C) the summary of two independent experiments.

3.3
3.3.1

Studying NK cell function in vivo in hu-NSG mice
Distribution and phenotype of NK cells in hu-NSG mice

NK cells are important effector cells contributing to the host response against pathogens
and tumors. To assess their functions in vivo, we first decided to analyze their
distribution and phenotype. In human PBMCs, NK cells are routinely identified as CD3CD56+ cells, however, in the peripheral blood of hu-NSG mice we detected only few
CD3-CD56+ cells (routinely <0.5%, data not shown). Recent research characterizing
mouse NK cells has established the surface marker NKp46 as an universal NK cells
marker. Hence, we decided to analyze peripheral blood and spleen for the presence of
CD3-NKp46+ cells (Figure 27 and data nor shown). Interestingly, 12 weeks after
reconstitution around 2-5 % of CD45+ cells in the blood were CD3-NKp46+ NK cells.
While around 75 % to 95 % of CD3-CD56+ cells expressed also NKp46, only 50 % of
CD3-NKp46+ cells expressed CD56 (Figure 27) indicating that NKp46 is a better marker
for NK cells in hu-NSG mice. We further analyzed these cells and found that they
expressed activating receptors such as NKp30, and NKG2D, and also inhibitory
receptors such as NKG2A/CD94, or KIRs. Notably, the frequency of CD3-NKp46+
expressing C-type specific KIRs was relatively low after 12 weeks, but based on a
limited numbers of mice, it seems that this frequency increases with time. Another
interesting observation is that around 50 % of CD3-NKp46+ cells do not express CD16
and this subset is therefore enriched in reconstituted mice. Finally, in addition to blood
and spleen, NK cells were also detected at similar frequencies in organs such as lymph
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nodes, lung, and liver, only in the bone marrow NK cells were present a lower
frequencies (Figure 28 A and B). The observed phenotype of NK cells in these organs
resembles that of NK cells in blood or spleen. In summary, CD3-NKp46+ cells expressing
a number of additional NK cell markers develop in hu-NSG mice, but they seem to be
enriched in early development stages like CD56+CD16-, possibly due to the lack of NK
cell differentiation signals.

+

Figure 27: NKp46 is superior compared to CD56 to identify human NK cells in hu-NSG mice. 12
+
weeks after reconstitution, splenocytes were used to identify NK cells by gating on (A) CD3 CD56 cells and
+
+
+
(B) CD3 NKp46 cells. Then, CD3 CD56 cells and CD3 NKp46 were analyzed for additional NK cell
markers. Data shown are from one representative mouse out of six mice reconstituted with two different fetal
livers (n = 3 each).
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Figure 28: CD3-NKp46+ NK cells are present in multiple organs in hu-NSG mice. (A) CD45+ cells from
the spleen, heparinized blood, perfused lung and liver as well as bone-marrow from one representative
mouse were analyzed 12 weeks after reconstitution, numbers indicate the frequency of CD3-NKp46+ cells of
CD45+ cells. (B) Summary of six mice reconstituted with two different fetal livers (n = 3 each).

3.3.2

Functional analysis of NK cells from hu-NSG mice in vitro

NK cells in mouse and man have a number of important functions during immune
responses, the two most important being the killing of target cells such as virus-infected
cells and secondly, the secretion of cytokines such as IFN- that modulate functions of
immune cells such as DCs and have direct effects on pathogen-infected cells. To
characterize the functional capabilities of NK cells developing in hu-NSG mice, bulk
splenocytes were co-cultured with K562 and CEM cells, two classical NK target cell
lines. PBMCs from healthy donors were used as control and when co-cultured with K562
and CEM cells, around 30 % of NK cells degranulated. After co-culture with K562 cells,
NK cells also produced IFN- demonstrating full functional maturation as previously
described (Figure 29B). However, significant fewer NK cells from hu-NSG degranulated
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and no IFN- production was observed indicating a lower frequency of functional NK
cells (Figure 29A and B). Furthermore, compared to CD56dimCD16+ NK cells from
PBMCs, NK cells from hu-NSG contained very little perforin and granzyme B and no
difference was observed between CD16+ and CD16- cells (data not shown).

Figure 29: NK cells from hu-NSG mice have an impaired ability to produce IFN- after stimulation
with K562 cells. (A) Splenocytes from hu-NSG mice were cultured for 6 hrs with medium, with K562 cells or
CEM cells at an E:T ratio of 10:1 and with IL-12 and IL-15 (1 ng/ml each) in the presence of monensin (5
ug/ml). Numbers indicate the frequency of IFN-+ cells of CD45+CD3-NKp46+ NK cells. (B) After stimulation
as in (A), CD107a surface expression and IFN-g production of NK cells from hu-NSG mice was compared to
NK cells fo peripheral blood from human donors. Data represent results from three independent experiments
including eleven mice and three human donors.
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This lack of proteins of the cytolytic machinery was also directly observed in assays
against K562 cells. Freshly isolated splenocytes were not able to efficiently lyse K562
cells, in contrast, NK cell lines established from these splenocytes were able to lyse a
number of classical NK target cell lines such as K562, CEM and LCL721.221 (Figure 30
and data not shown). These results indicate that NK cells in hu-NSG mice are resting or
immature as they lack natural cytotoxicity, which is a property of regular circulating NK
cells in humans.

Figure 30: IL-2-activated NK cell lines are highly cytotoxic. Polyclonal NK cell lines were generated from
splenocytes of hu-NSG in low-dose IL-2. After 7 days, expression of perforin and granzyme B was compared
to NK cells in control PBMCs (A) and cytolytic ability gainst K562 cells was determined (B). Representative
data from two independent experiments.
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3.3.3

Activation of NK cells by poly(I:C) and IL-15

Recently, it was shown that resting murine NK cells have only very limited reactivity
towards target cells in the steady state, but NK cells upregulated both cytotoxicity and
IFN- production towards target cells upon short-term (<24 hrs) in vivo and in vitro
activation (Fehniger et al., 2007). Hence, splenocytes were cultured for 24hrs with
poly(I:C) and their reactivity towards K562 and CEM cells was compared to cells cultured
in medium alone. Indeed, poly(I:C)-activated NK cells showed a significantly higher
reactivity towards K562 and CEM cells than control cells (Figure 31A and B). Since IL-15
was recently described to be involved in the activation of NK cell effector functions in
murine NK cells, we then tested if human NK cells from hu-NSG mice could be similarly
activated by IL-12 and IL-15. Culture for 24 hrs in IL-12 and IL-15 together but also in IL15 alone, increased both degranulation and IFN- towards K562 cells to levels similar of
poly(I:C) (Figure 31A and B), indicating that in the steady state NK cells in hu-NSG mice
are less functional mature compared to healthy individuals, but that after activation they
are efficient effector cells. Notably, culture of splenocytes with IL-15 and poly(I:C) also
increased intracellular levels of perforin and granzyme B. (Figure 32) This is of particular
interest as murine NK cells also do not express perforin and granzyme B protein in the
steady state, but only after activation with IL-15.
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Figure 31: After in vitro pre-activation human NK cells from hu-NSG develop the ability to produce
IFN- after co-culture with K562 cells. Splenocytes were pre-cultured for 24 hrs in medium alone or with
p(I:C)(25 μg/ml), IL12 and IL-15, or IL-15 (1 ng/ml each). Then, splenocytes were cultured for 6 hrs with
medium, with K562 cells or CEM cells at an E:T ratio of 10:1 and with IL-12 and IL-15 (1 ng/ml each) in the
presence of monensin (5 ug/ml). (A) CD107a surface expression and (B) IFN- production of NK cells from
hu-NSG mice was compared to NK cells fo peripheral blood from human donors. Data represent results from
two independent experiments including four mice and two human donors.
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Figure 32: Increased expression of perforin and granzyme B protein in NK cells after preactivation in
vitro . Splenocytes were pre-cultured for 24 hrs in medium alone or with p(I:C)(25 μg/ml), IL12 and IL-15, or
IL-15 (1 ng/ml each). Intracellular expression of perforin and granzyme B in CD3-NKp46+ NK cells was
analyzed by flow cytometry. Data represent results from one experiment including four mice.

Next, we tested if NK cells could be also activated in vivo with either IL-15 or poly(I:C).
hu-NSG mice were injected with poly(I:C) and IL-15, and effector functions of
splenocytes from these mice were compared to those of control mice. Similar to the
previous in vitro cultures, NK cells from mice injected with both poly(I:C) and IL-15
showed increased reactivity towards K562 cells compared to control NK cells
demonstrating that human NK cells reactivitiy increased rapidly in vivo (Figure 33).
Again, we also observed a rapid increase of the intracellular perforin and granzyme B
protein levels after in vivo activation (data not shown). In summary, these results indicate
that NK cells developing in hu-NSG mice display an unusual phenotype and show in
functional assays a resting behavior.
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Figure 33: Human NK cells from hu-NSG acquire after in vivo activation the ability to produce IFN-
after co-culture with K562 cells. Hu-NSG mice were injected i.p. with PBS or with p(I:C)(50 μg/mouse).
Then, splenocytes were cultured for 6 hrs with medium, with K562 cells or CEM cells at an E:T ratio of 10:1
and with IL-12 and IL-15 (1 ng/ml each) in the presence of monensin (5 ug/ml). CD107a surface expression
and IFN- production of NK cells from hu-NSG mice was analyzed. (A) shows the representative results from
two mice, (B) is the summary of two experiments with a total of eight mice.
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4
4.1

Discussion
Innate Immune control of EBV infection

NK cells and DCs are central figures in the innate immune response, and have been
shown to interact in early phases of murine herpes virus infections (Andoniou et al.,
2005; Andrews et al., 2003; Kassim et al., 2006). In contrast to the mouse, humans
possess the CD56brightCD16- subset of NK cells, which rapidly secretes high IFN- levels
and strongly proliferates upon activation by DCs (Vitale et al., 2004). These NK cells are
enriched in secondary lymphoid organs like tonsils and lymph nodes, and are therefore
strategically positioned to rapidly respond to pathogens at these sites (Fehniger et al.,
2002; Ferlazzo et al., 2004a; Ferlazzo et al., 2004b). Such a pathogen is the human
tumor virus EBV, which enters the human body through the tonsils after transmission via
saliva exchange. Within tonsils of healthy virus carriers, the proliferation program, which
is also observed in in vitro EBV infected B cells, was found in naïve B cells, which travel
through the perifollicular T cell zone and follicular mantle zone to encounter antigens
(Babcock et al., 2000; McHeyzer-Williams and McHeyzer-Williams, 2005). These areas
were also described to harbor DC/NK cell interactions or are close vicinity to those areas
(Bajenoff et al., 2006; Ferlazzo et al., 2004a; Garrod et al., 2007). Our data suggest that
at these sites, human DCs can activate preferentially CD56bright CD16- NK cells, which
then become able to limit EBV-mediated B cell transformation, mainly by secretion of
IFN-, and regulate the proliferation program of EBV latency via this cytokine. Restriction
of EBV induced B cell transformation by NK cells probably curtails viremia until it can be
efficiently immune controlled by the adaptive immune system. These results suggest for
the first time an important effector function for tonsillar NK cells early in the primary
immune response against human persistent and oncogenic EBV.
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4.1.1

Sensing EBV infection by the immune system

iDCs patrol the periphery and act as sentinels for the immune system (Banchereau and
Steinman, 1998). Upon direct infection by a pathogen or uptake of pathogen-containing
material in conjunction with a maturation stimulus they migrate to secondary lymphoid
organs carrying information both in the form of a particular maturation pattern and
pathogen constituents. DC maturation changes drastically the properties of DCs
converting them into potent activators of both the innate and adaptive immune system.
One group of DC receptors that detect pathogenic determinants and trigger the
activating functions of DCs are TLRs (Iwasaki and Medzhitov, 2004). In murine herpes
virus infections, it has been shown that different pathways synergize for the activation of
immune responses against these pathogens. TLR9-deficient mice as well as TLR3- and
TLR2-deficient mice have increased MCMV titers, suggesting that the immune system
uses complementing recognition systems in herpes virus infection (Andoniou et al.,
2005; Krug et al., 2004; Tabeta et al., 2004). Similarly, EBV might activate human DCs
by means of several pathways. In addition to TLR9-activating CpG-motifs, by which EBV
activates human plasmacytoid DCs (Lim et al., 2006), the EBV genome supports
convergent transcription, which occurs also in other DNA viruses such as herpes simplex
virus-1 (HSV-1)(Lagunoff and Roizman, 1994; Sample et al., 1989). The resulting virally
encoded dsRNAs have been isolated from HSV-1-infected cells (Jacquemont and
Roizman, 1975). Indeed, we were able to demonstrate that dsRNA from the
convergently transcribed LMP1 and LMP2A antigens of EBV was able to stimulate IL-12
secretion. The measured IL-12 amounts were similar to levels secreted by CD11c+ DCs
after exposure to live virus and heat-inactivated EBV particles. Consequently, we
suggest that myeloid DCs can detect EBV either directly, or indirectly through EBVderived dsRNA as TLR3 and mda-5 agonists during primary infection and subsequently
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initiate the immune response by activating NK cells and priming of T cells (Gitlin et al.,
2006; Schulz et al., 2005). In line with previous studies, we find that phenotypical
markers such as MHC class II and costimulatory molecules are equally upregulated with
various DC maturation stimuli, while cytokine secretion profiles varied dramatically
between different DC maturation conditions (Mailliard et al., 2004). In particular, IL12p70, a potent stimulator of NK cells and Th1 responses, was produced at higher levels
by DCs exposed to EBV, or matured with EBV-derived dsRNA or with maturation
cocktails containing the dsRNA analog poly(I:C), compared to immature DCs or DCs
matured with proinflammatory cytokines or LPS. Nonetheless, even low levels of IL-12
secreted by LPS-matured DCs through directed secretion into the synapse between NK
cells and DCs have been shown to activate NK cells (Borg et al., 2004). Hence, our data
suggests that myeloid DCs are able to sense EBV infection and to stimulate NK cell
responses during primary EBV infection at least in part via IL-12.

4.1.2

NK cell mediated immune control of EBV infection

Two main functional subsets of NK cells have been described in humans, while
counterparts for these NK cell populations have not been identified in the mouse so far
(Cooper et al., 2001). The CD56dimCD16+ subset is mainly responsible for natural
cytotoxicity and ADCC, while the CD56bright CD16- subset has been characterized by its
unique capacity to produce high amounts of immunoregulatory cytokines, such as TNF,
IFN- and GM-CSF, upon activation (Cooper et al., 2001). IFN- production by
CD56brightCD16- NK cells, as well as NK cell proliferation are rapidly induced by DCs
(Vitale et al., 2004). In addition, DCs also augment cytotoxicity of this subset after
prolonged activation (Ferlazzo et al., 2004b). Several studies indicate a role for NK cells
in the control of EBV infection and in particular in early primary immune responses
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(Kaplan and Shope, 1985; Masucci et al., 1983; Moretta et al., 1997; Wilson and
Morgan, 2002). However, all in vitro studies up to now have used blood NK cells
activated by IL-2, which is, at least in humans, mostly secreted by activated T cells and
therefore presumably not present during innate immune responses. Hence, we focused
on NK activation by DCs as a physiological NK cell stimulus present during the early
immune response to primary virus infections. Furthermore, previous studies on the role
of NK cells during EBV infection mainly emphasized cytotoxicity, but not IFN- secretion
of NK cells, although lymph node- and tonsil-resident NK cells primarily release
cytokines after activation (Fehniger et al., 2002; Ferlazzo and Munz, 2004; Ferlazzo et
al., 2004a). Suggesting a prominent role for NK cell-derived cytokines early during EBV
infection, earlier studies have found that recombinant IFN- is protective for several days
during initial B cell transformation by EBV, whereas in contrast, type I interferons inhibit
transformation only during the first hours after infection (Lotz et al., 1985). Moreover,
EBV-specific CD4+ and CD8+ T cells have been reported to mediate regression of EBVtransformed B cells despite low to undetectable cytolytic activity (Lee et al., 2004; Shi
and Lutz, 2002). Our data support the hypothesis that tonsillar NK cells restrict efficiently
EBV-induced B cell transformation via their superior ability to produce IFN- upon DC
activation. Although IL-12 and IFN- secreted by poly(I:C) DCs and DC1s upregulate
cytotoxicity of NK cells, autologous EBV transformed B cells are not efficiently killed by
activated NK cells due to their high MHC class I expression (Pappworth et al., 2007).
Instead, the results of our studies support a prominent role for IFN- in the innate
immune response to EBV by NK cells. First, addition of recombinant IFN- to the
regression assay decreased the number of transformed B cells. Second, IFN- levels,
sufficient to restrict EBV-induced B cell transformation, were found in our regression

101

cultures. Finally, blocking of IFN- in regression assays with NK cells significantly
decreased the protective effect of NK cells. Hence, we conclude that this cytokine
significantly contributes to innate resistance against primary EBV infection. In addition to
its direct antiviral activity, IFN- secreted by DC-activated NK cells might also shape the
EBV-specific adaptive immune response favoring a Th1-polarization which is observed
in EBV-positive individuals (Bickham et al., 2001; Laouar et al., 2005; Martin-Fontecha et
al., 2004; Morandi et al., 2006). Therefore, contrary to the notion that NK cells respond
primarily with cytotoxicity without prior activation, we demonstrate that their main function
against a relevant human pathogen consists of cytokine secretion after activation by
DCs.

4.1.3

Interference of IFN- with the establishment of EBV latency

The effects of IFN- in innate immunity are manifold, ranging from strengthening intrinsic
immunity via the induction of antiviral factors or degradative pathways in exposed cells,
to the activation of other innate lymphocytes such as macrophages (Schroder et al.,
2004). EBV transforms B cells by the coordinate expression of EBV latency genes that
provide signals for B cell survival and proliferation. Of the eight latent EBV antigens,
LMP1 has been suggested to be the main oncogene of the virus, causing epithelial cell
transformation in vitro and B cell transformation in vivo (Dawson et al., 1990; Fahraeus
et al., 1990; Kulwichit et al., 1998). When we analyzed viral gene expression upon
exposure of cells to IFN-, we only detected differences in the levels of LMP1 mRNA, but
not in any of the other viral mRNAs characterized. These genes included also the
recently described anti-apoptotic proteins BALF1 and BHRF1 essential for the
transformation of B cells by EBV (Altmann and Hammerschmidt, 2005). Therefore, IFN-
induced down-regulation of LMP1 transcription could be one mechanism by which DC-
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activated NK cells limit EBV induced B cell expansion. The fairly late transcription of
LMP1, compared to other EBV latent antigens, during the establishment of EBV latency
could also explain why IFN- can restrict B cell transformation by EBV during the first
days of primary EBV infection, while others and we found that IFN- was not able to
inhibit proliferation of fully EBV transformed LCLs (Lotz et al., 1985; and data not
shown). Similarly, IFN- secretion by NK cells was shown to limit MCMV infection during
the first week of infection, and reduced immediate early or late MCMV gene
transcription, depending on the infected cell type (Orange et al., 1995; Presti et al.,
2001). Therefore, tonsillar NK cells might limit latent EBV infection by IFN- mediated
down-regulation of LMP1 until adaptive T cell immune responses can eliminate fully
EBV-transformed B cells.

4.1.4

NK cell mediated innate immune control of EBV infection

Originally, NK cells were thought to be primarily cytotoxic effector cells. However, recent
studies have highlighted cytokine-mediated immunoregulatory and anti-viral functions of
NK cells. Interaction between NK cells and DCs were found to be essential for the proper
activation of NK cell function during infection with bacteria and viruses. Based on the
results of this study, we suggest that human myeloid DCs stimulate NK cells during EBV
infection primarily via their ability to secrete IL-12. Activated NK cells are then able to
mediate regression of EBV-mediated B cell transformation. Tonsillar NK cells, which, like
lymph node NK cells, produce higher levels of IFN- than their peripheral blood
counterparts after activation by DCs, are superior in inhibiting EBV-induced B cell
transformation in vitro by down-regulating important components in the proliferation
program of EBV latency. These results suggest a novel and important effector function
for tonsillar CD56brightCD16- NK cells upon DC activation in the primary immune response
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against EBV. In addition to this non-cytolytic mechanism, a recent study demonstrated
that upon exposure to IFN- NK cells were able to lyse EBV-infected cells during the
lytic phase (Pappworth et al., 2007). Notably, another study demonstrated that pDCs are
able to sense EBV and activate NK cell by secretion of IFN- suggesting that NK cells
might provide innate protection against EBV at different point during the viral life cycle
(Lim et al., 2006). Beyond EBV infection, our data suggest that humans have a
strategically well-positioned population of NK cells that directly combat pathogen entry at
mucosal sites and might restrict pathogens until they can be cleared or controlled by
adaptive immunity.

Figure 34: NK cell mediated non-cytolytic immune control of EBV infection after activation by DCs. EBV
enters the tonsil and is sensed by cDCs using PRR. DCs mature, upregulate CD83 and start to produce
IL12p70. This activates CD56brightCD16- tonsillar NK cells to produce IFN- that limits transformation of B
cells by EBV.
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4.2
4.2.1

Establishment of a humanized mouse models for EBV infection
Multilineage reconstitution of immune cells in hu-NSG mice

Recently, several groups developed independently a number of different severely
immunodeficient mouse models that support the multi-lineage reconstitution of human
immune cells in vivo (Gimeno et al., 2004; Ishikawa et al., 2005; Melkus et al., 2006;
Shultz et al., 2005; Traggiai et al., 2004). In our laboratory we obtained higher
reconstitution of human cells in NSG mice described originally by Shultz et al than in
Rag2-/-c-/- mice on a mixed 129/Balb/c background described by Gimeno et al. However,
it is difficult to generalize that NSG are better hosts as the ability of Rag2-/-c-/- mice to
support reconstitution of human cells strongly depends on the mouse background.
Strikingly, C57BL/6 Rag2-/-c-/- do not support reconstitution and we were not able to test
pure-bred Balb/c Rag2-/-c-/- which support higher reconstitution than mixed 129/Balb/c
Rag2-/-c-/- (R. Flavell, personal communication). However, a polymorphism in the Sirpa
gene was recently described to be responsible for improved human hematopoiesis in
NOD mice compared to other mouse strains (Takenaka et al., 2007). Therefore, the
NOD background might be currently the most suitable for human hematopoietic
reconstitution in mice.
We obtained regularly high levels of engraftment in NSG mice as detected in the blood,
spleen, and other non-lypmhoid organs such as liver, kidney and the lung. We detected
comparable frequencies of cells from all lymphoid lineages (B cells, T cells, NK cells), as
well as conventional and plasmacytoid dendritic cells and also CD14+ monocytes in large
groups of animals engrafted with cells from the same donor. Notably, CD14+ monocytes
were almost absent in spleens of hu-NSG, while they were regularly detected in the
blood and bone marrow (data not shown and M. Pack, personal communication). Since
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hu-NSG presumably have all the necessary components to raise functional immune
responses, we decided to test hu-NSG mice as a model for in vivo EBV infection and
antiviral T cell-mediated immune control.

4.2.2

EBV infection of hu-NSG mice

Since

no

similarly

oncogenic

-herpesviruses

of

the

EBV

containing

genus

lymphocryptoviridae has been identified in rodents to date and murine cells do not
support the EBV life cycle, an appropriate small animal models for EBV is lacking
(Ehlers et al., 2008; Zychlinska et al., 2008). Immunodeficient mice have served as host
for development of lymphoproliferative diseases after transfer of PBMCs from seropositive individuals, and also for de novo infection of B cells developing from
transplanted CD34+ stem cells (Fuzzati-Armentero and Duchosal, 1998; Islas-Ohlmayer
et al., 2004). However, these early models did not allow performing longitudinal studies
of primary EBV infection in the interplay with a functional human immune response. In
order to test if hu-NSG can be infected with EBV, we injected increasing doses of EBV
intra-peritoneal. We detect CD20+EBER+ B cells in the white pulp region of the spleens in
low numbers after 4-6 weeks after infection, but we did not find other EBV+ cell type,
which was confirmed in other studies (Cocco et al., 2008; Traggiai et al., 2004; Yajima et
al., 2008). EBV+ cells were always surrounded by CD3+ T cells, even in the rare cases
when we detected CD20+EBER+ cells in non-lymphoid organs such as liver and kidney.
Depending on the dose of EBV used for infection, we detected higher frequencies of
EBV+ cells and even stronger expansion CD8+ T cells, resembling IM. Notably, a similar
association between EBV dose and CD8 T cell expansion was confirmed in another
recent study (Yajima et al., 2008). Hu-NSG infected with lower doses of EBV survived
over long periods of time (>12 weeks), while NOD-scid mice transplanted with CD34+
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cells that do not develop T cells died within 4-5 weeks upon EBV infection indicating the
presence of successful immune control in hu-NSG mice (Islas-Ohlmayer et al., 2004).
EBV infected B cells were almost always also strongly positive for EBNA2, and to lower
levels for LMP1 indicating a latency III expression pattern, again, similar results were
observed in two similar studies (Traggiai et al., 2004; Yajima et al., 2008). These results
demonstrate that hu-NSG mice can serve as an in vivo model for EBV infection and that
immune control of EBV seems to curtail disease.

4.2.3

EBV-specific immune responses in humanized mouse models

Previous studies employing different models of humanized mice have demonstrated that
humanized mice can be infected with EBV, but failed to demonstrate clearly the
induction of protective EBV-specific immune responses (Melkus et al., 2006; Traggiai et
al., 2004). In BLT mice, EBV infection elicited low levels of IFN- secreting, HLA
restricted T cell responses against autologous EBV transformed B cells (Melkus et al.,
2006), and in reconstituted BALB/c Rag2-/-c-/- mice T cell proliferation against autologous
EBV transformed B cells was detected after EBV infection (Traggiai et al., 2004). In none
of these animal models, however, the protective value of EBV specific primary T cell
responses has been investigated in vivo. Depending on the EBV dose used for infection,
we detected increasing amounts of IFN- producing T cells that were restricted by MHC
class I and II demonstrating the priming of human HLA-restricted T cell responses in vivo
in hu-NSG mice. Notably, the frequency of IFN- producing T cells number was about
five to tenfold higher than in a previous study (Melkus et al., 2006). We indirectly
demonstrated that IFN- was mainly secreted CD8+ T cells as it was strongly reduced
after using MHC class I blocking antibodies in most experiments. Again, similar results
were obtained in the other studies (Melkus et al., 2006; Yajima et al., 2008). In order to
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identify the specificities of EBV-specific T cells, we cloned T cells from mice infected with
EBV after enrichment by classical limiting dilution. We were able to obtain a number of
LCL-specific CD4+ and CD8+ T cell clones that exhibited both cytotoxicity and IFN-
secretion against autologous EBV transformed B cells. However, we were only able to
identify the peptide specificity of one CD8+ T cell clone that recognized a subdominant
LMP1 epitope (LMP1167-176). These results clearly demonstrate that hu-NSG mice can
prime EBV-specific immune responses upon primary EBV infection in vivo, but it
remained unclear if they were protective.

4.2.4

Priming of protective CD4+ and CD8+ T cell responses in hu-NSG mice

Since we reported that EBV infection in hu-NSG mice elicited cytotoxic and epitope
specific primary T cell responses in vivo, we decided to test if these T cell responses are
truly protective. In our initial experiments we decided to deplete both CD4+ and CD8+ T
cells simultaneously by injection of anti-CD4 and anti-CD8 antibodies. Mice that received
T cell depleting antibodies had highly increased frequencies of EBV+ tumors in multiple
organs and also had increased viral titers in the spleen demonstrating that hu-NSG mice
are able to prime protective tumor-specific T cell responses in vivo. In order to dissect, if
only CD8 T cells are necessary for the immune control of EBV in vivo, we also
performed experiments in which we compared the depletion of either CD4+ T cells or
CD8+ T cells to the depletion of both subsets. Interestingly we found that both CD4+ and
CD8 T cells contributed to the control of EBV infection in hu-NSG mice. Based on the
results of our in vivo experiments, we conclude that CD4+ T cells contribute to the control
of early EBV infection, but are not able to restrict viral replication efficiently in the
absence of CD8+ T cells. However, upon additional depletion of CD8+ in addition to CD4+
T cells viral titers are further elevated, suggesting that CD4+ T cells can mediate some
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immune control of EBV (Heller et al., 2006). The inability of CD8+ T cells to control EBV
infection on their own, might reflect the requirement for CD4+ T cell help during primary
EBV infection (Bevan, 2004). This analysis demonstrates the usefulness of our in vivo
model which allows for the first time to dissect protective mechanisms of human
lymphocyte compartments in vivo.

4.2.5

Limitations of hu-NSG mice as model for EBV infection

Although we demonstrate protective primary immune responses against EBV in hu-NSG
mice, there are a number of limitations to this model. Primary immune responses control
EBV infection at high levels of viral load, with massive expansion and activation of the
CD8+ T cell compartment. These features are reminiscent of symptomatic primary EBV
infection. Such a phenotype seems to be even more pronounced in hu-NSG mice,
because they carry a tenfold elevated viral load in their splenocytes, compared with
approximately 104 viral DNA copies per 106 peripheral blood mononuclear cells in IM
patients (Fafi-Kremer et al., 2005; Hochberg et al., 2004). This of course assumes that
the frequency of EBV infected cells is similar in peripheral blood and spleen during IM,
as has been shown for healthy virus carriers (Laichalk et al., 2002). The reconstituted
human immune system in hu-NSG mice has therefore difficulty controlling EBV infection,
similar to chronic active EBV infection (CAEBV) in bone marrow transplantation
recipients. Indeed, around 105 viral DNA copies per 106 peripheral blood mononuclear
cells have been observed in more than 50% of CAEBV patients, and these also develop
occasionally tumors (Kimura et al., 2001; Miyamura et al., 2008). Nevertheless, the
reconstituted human immune system protects most infected mice from EBV associated
malignancies. Furthermore, EBV specific T cell response in hu-NSG mice seems to favor
subdominant EBV derived peptide epitopes (Hislop et al., 2007), and we were unable to
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detect T cells of in humans dominant specificities ex vivo. A possible explanation for this
might be the sub-optimal selection of human T cells and their TCRs on mouse thymic
epithelial cells and on human BM-derived cells. Even so others and we have reported
that human T cells recognize EBV-infected B cells after EBV infection of hu-NSG mice,
and this recognition can be blocked with antibodies against human MHC molecules, the
selection of EBV-specific T cells on human BM-derived cells and due to cross-reactivity
with H2 molecules on mouse stromal cells seems to favor different affinities and
specificities than those observed in humans with matching MHC type.
Another important process that is impaired in hu-NSG mice is the generation of highaffinity antibodies probably due to the lack of germinal center formation and classswitched humoral immune responses. Although we found low concentrations of human
IgG accumulating in the plasma of reconstituted mice over time, we were unable to
detect by ELISA EBV specific IgG or IgM responses against the viral capsid antigen
(VCA) in EBV infected mice (data now shown). Interestingly, another study found by
western blot that 4 of 30 EBV-infected hu-NSG mice developd antibodies against
recombinant BFRF3, a component of the VCA (Yajima et al., 2008). We cannot exclude
that humoral responses might develop against other EBV antigens in our model and
perhaps at later timepoints of infection, as we have observed for EBNA1 in an
experimental vaccine study using the same mouse model (Gurer et al., 2008).
Accordingly, because more restricted expression patterns of EBV latent antigens have
only been found in germinal center B cells of healthy virus carriers and since latency I/II
tumors are thought to originate from EBV infected centrocytes or centroblasts, the study
of EBV associated Burkitt and Hodgkin lymphomas and T cell responses against these
malignancies might be difficult in hu-NSG (Babcock et al., 2000; Kuppers, 2003).
Latency II tumors, however, have been observed in EBV infected and human B cell
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reconstituted NOD-scid mice, suggesting that these hosts allow signaling for germinal
center formation. Because these mice are unable to reconstitute human T cells after
HSC transfer alone, immunological studies are not possible in this model (IslasOhlmayer et al., 2004).
In addition to these limitations regarding the selection and proper maintenance of human
B cells and T cells in hu-NSG mice, there are a number of other properties of hu-NSG
that need to be further improved to generate humanized mouse models that will be of
true value for scientist studying human immunology. As briefly discussed human myeloid
cells are rare in humanized mice, most probably because human myeloid progenitors
can not compete with their mouse equivalents to repopulate lymphoid and non-lymphoid
organs (Manz, 2007). It has been suggested that the genetic replacement of murine
cytokines with their human equivalents would favor human myeloid cells and could lead
to improved engraftment. Along similar lines, it has been suggested that the in vivo
maintenance of human CD34+ cells could be also improved leading to increased longterm output of human cells. This could potentially also lead to decreased number of
human CD34+ stem cells necessary for reconstitution which could be become a major
issue because of limited supply and potential ethical considerations regarding the use of
fetal tissues.

Table 7: Limitations of current humanized mouse models
Problem:
Scarce human stem cells are
necessary for every mouse
Impaired maintenance of human
hematopoietic stem cells.
Human myeloid cell differentiation
Human T and B cell selection
and maintenance

Proposed solutions:
Expansion of HSC or differentiation of HSC from
ESC
Expression of human cytokines or transplantation of
mesenchymal stem cells
Expression of human cytokines with preferentially
weak or non-mouse cross-reactivity (GM-CSF, IL-3)
Expression of human MHC class I and II instead of
mouse MHC molecules.
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4.2.6

Improved detection of EBV-specific immune responses in HLA-A2
transgenic hu-NSG mice

In order to address one of the previously discussed issues, the selection and
maintenance of human T cells, we characterized the overall reconstitution and
generation of HLA-restricted immune responses in HLA-transgenic NSG mice. We
reconstituted HLA-A2 transgenic NSG mice with HLA-A2+ CD34 stem cells and observed
similar levels of reconstitution between transgenic and non-transgenic animals. Upon
infection with EBV, we detected for the first time the recognition of HLA-A2 restricted in
humans dominant T cell epitopes by CD8+ T cells from HLA-A2 transgenic mice. This
demonstrates that the short-coming of dominant EBV epitope recognition during infection
in NSG mice can be overcome by introducing HLA transgenes, like in our case HLA-A2,
into this mouse background. We were able to detect both latent and lytic EBV antigen
specific T cell responses against dominant peptide epitopes from EBV infected hu-NSGA2 mice ex vivo. Interestingly and similar to human EBV carriers, lytic EBV specific T
cells were detected with nearly one log higher frequencies than latent EBV antigen
specificities (Münz, 2005). Therefore, HLA transgenes seem to overcome one of the
limitations

of

human

immune

responses

in

hu-NSG

mice,

and

allows

this

immunocompetent small animal model with human immune system components to
develop protective T cell responses against EBV infection with similar specificities to
human virus carriers. Because EBV specific T cells are considered to be the cornerstone
of immune control against this oncogenic and persistent -herpesvirus (Hislop et al.,
2007; Khanna and Burrows, 2000), we propose to characterize the innate and adaptive
immune responses that lead to this T cell based immune control further. We also plan to
evaluate vaccine candidates for eliciting these protective T cell responses against EBV
and other pathogens with exclusive tropism for the human hematopoetic lineage. This

112

includes the human immunodeficiency virus (HIV), which has been shown to establish
infection in mice with reconstituted human immune system components (An et al., 2007;
Baenziger et al., 2006; Berges et al., 2008; Gorantla et al., 2007; Sun et al., 2007;
Watanabe et al., 2007; Zhang et al., 2007)

4.3

NK cell development and function in hu-NSG mice

Extensive studies of murine NK cells demonstrated that NK cells participate in vivo in the
innate immune responses against pathogens and the immunosurveillance of tumor cells
(Biron et al., 1999; Trinchieri, 1989). The developmental pathways leading to generation
of NK cells have been mainly analyzed in genetically manipulated mice and provided
valuable insight into the generation of subsets of NK cells in the mouse (Huntington et
al., 2007). However, the study of human NK cells have been hampered by lack of
suitable model systems as in vitro models offer some insight into development and
functions of human NK cells, but naturally lack the value of in vivo experimentation.
Importantly, significant differences between NK cells in mice and humans have been
noted (Table 1) that increase the difficulty to translate results obtained in mouse models
to human immunology and finally to clinical practice (Mestas and Hughes, 2004). A
recently developed model attempts to close this gap by generating a small animal model
to study function and development of human immune cells (Shultz et al., 2005; Traggiai
et al., 2004). We used this model to study adaptive immune responses against EBV, but
also reasoned to use this model to study specific aspects of human NK cell function.

4.3.1

Phenotypical analysis of human NK cells in hu-NSG mice

In line with previous reports we detected human CD3-CD56+ cells in immunodeficient
mice reconstituted with human CD34+ stem cells (Figure 27)(Ishikawa et al., 2005;

113

Traggiai et al., 2004). However, we realized that by co-staining with anti-NKp46 we could
identify cells that were CD3-CD56-/lowNKp46+ NK cells that expressed uniformly other
activating NK receptors such as NKp30 and NKG2D and inhibitory receptors such as
CD94/NKG2A.

Hence, we decided in the following to detect human NK cells using

NKp46, one of the three human NCRs, that is expressed already early during NK cell
development and was also recently proposed as a unique NK cell marker in the mouse
(Huntington et al., 2007; Walzer et al., 2007). NK cells were detected in all organs
analyzed, demonstrating that human NK cells can migrate to multiple sites in humanized
mice. But in contrast to NK cells in human PBMCs, we noted that only around 50 % of
NK cells expressed CD16 showing that the CD16- NK cell subset is enriched in
humanized NSG mice. Interestingly in humanized Balb/c Rag2-/-c-/- mice, a recent study
did not find such an enrichment of CD16- NK cells (Huntington et al., 2009), while the
expression of the CD16 was not analyzed in the other studies (Ishikawa et al., 2005;
Traggiai et al., 2004). In comparison, we observed additionally in some organs a
significant difference in the frequency in of human NK cells in NSG mice compared to
published frequencies in Balb/c Rag2-/-c-/- (Huntington et al., 2009). While frequencies in
the latter were around 0.2 % of human CD45+ cells in the spleen, we detected
frequencies of around 2% of human CD45+ cells. However, in the bone marrow this
difference was not detectable, which could potentially indicate that early NK cell
development in the bone marrow is similar but that NK cell survival in the periphery is
increased in humanized NSG mice. It was hypothesized that the low frequency of NK
cells in Balb/c Rag2-/-c-/- is potentially due to limiting amounts of IL-15 being transpresented by IL-15R on human myeloid or stroma cells as murine IL-15 does not crossreact on human cells (Huntington et al., 2009). One might speculate that IL-15 levels are

114

higher in hu-NSG mice compared to Balb/c mice, but this issue remains elusive and
needs to be addressed in the future. Nevertheless, based on these results and our own
observations, we conclude that hu-NSG may serve as a valuable model to study specific
questions related to human NK cell function and development.

4.3.2

Functional analysis of NK cells in hu-NSG mice

NK cells were originally described as naturally-active cells displaying readily effector
functions towards tumor and virus-infected cells (Herberman et al., 1975a; Herberman et
al., 1975b). However, closer characterization of murine and human NK cells in vitro,
demonstrated that resting NK cells display minimal effector functions towards tumor cells
and after triggering their activating receptors (Bryceson et al., 2006; Fehniger et al.,
2007). Indeed, numerous studies have found that NK cell effector functions are
increased upon activation by ligands for PRR such as poly(I:C) or synthetic cytokines
such as type I interferons, IL-2, IL-12, and IL-15 (Djeu et al., 1979; Gidlund et al., 1978;
Orange and Biron, 1996b). Particularly, IL-15 was recently described to be essential for
the priming of murine NK cells after exposure to ligands of PRR (Lucas et al., 2007). In
order to characterize the functional properties of human NK cell in hu-NSG mice, we
cultured splenocytes with two classical NK cell target cell lines, K562 and CEM. NK cells
from hu-NSG mice degranulated less than NK cells from human PBMCs after co-culture
with K562 cells, and more strikingly, NK cells from hu-NSG mice did not produce any
IFN- compared to NK cells from PBMCs. In order to test if human NK cells from hu-NSG
acquire more effector function after in vitro activation, splenocytes were preactivated with
poly(I:C) or IL-12 and IL-15. Strikingly, increased numbers of pre-activated NK cell
degranulated and produced IFN- after exposure to K562 and CEM cells compared to
unstimulated cells. These results suggest that human NK cell in hu-NSG mice require
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similarly to murine NK cells to receive additional signals to become effective effector
cells, in particular since IL-15 alone had a similar effect. To further test this hypothesis,
we injected hu-NSG mice with poly(I:C) to activate NK cells in vivo. Again, preactivated
NK cells displayed increased effector functions with higher numbers of cells
degranulating and producing IFN- after exposure to K562 and CEM cells. In addition to
directly detecting the effector functions of NK cells, we also measured the expression of
proteins important for the cytotoxic functions of NK cells, perforin and granzyme B. This
is of particular interest since it was recently described that resting murine NK cells do
contain perforin and granzyme B mRNA but lack perforin and granzyme B proteins and
that activation with IL-15 induces the translation of their mRNAs (Fehniger et al., 2007).
Upon culture of splenocytes in vitro with poly(I:C) or IL-15, NK cells strongly upregulated
the expression of perforin and granzyme B proteins. From these results we conclude
that human NK cells in hu-NSG mice require similarly to murine NK cells activating
signals to become fully equipped effector cells. One might speculate that the different
environment in which hu-NSG mice and healthy human individuals live in and the
pathogens that they are exposed to can explain the differences between human NK cells
from these hosts. In contrast to hu-NSG mice and other laboratory mice that do live
under specific-pathogen-free conditions and receive autoclaved food and water, humans
are continuously exposed to various pathogens. These sub-clinical infections might
induce a continuous arming or priming of NK cells leading to increased effector functions
in the steady-state which can be further enhanced during infection and inflammation.
However, the difference between human NK cells from hu-NSG mice and healthy
individuals might also be explained by differences in development of human NK cells in
hu-NSG mice potentially due to a sub-physiological levels of soluble or trans-presented
IL-15. In order to support the first hypothesis, it would be very interesting to analyze the
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expression of perforin and granzyme B protein in NK cells from mice living in the wild in
comparison to animals kept in the laboratory. In conclusion, hu-NSG mice represent a
novel in vivo model to study the development of NK cells from CD34+ HSC in a dynamic
environment. It will also be of high interest to study the interactions of NK cells with other
human immune cells in hu-NSG mice in the steady-state and in the context of viral
infections such as EBV.
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